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Abstract
Cellular senescence a specialized form of growth arrest that contributes to the pathogenesis of
several aging-related disorders including cancer. While by definition tumor cells are considered
immortalized, they can undergo senescence when exposed to conventional and targeted cancer
therapy. Therapy-Induced Senescence (TIS) represents a fundamental response to therapy and
impacts its outcomes. However, TIS has been considered a positive therapeutic goal since
senescent tumor cells are expected to enter a state of permanent growth abrogation. In this work
we examined the hypothesis that a subpopulation of senescent cells can re-acquire proliferative
potential after a state of senescent dormancy, indicating that senescence is not obligatorily an
irreversible process. Our observations indicate that H460 non-small cell lung cancer cells induced
into senescence by exposure to etoposide, and enriched based on β-galactosidase staining and size,
were shown to recover reproductive capacity, which was accompanied by resolution of the DNAdamage-response (downregulation of p53 and p21Cip1 induction), attenuation of the Senescenceassociated Secretory Phenotype (SASP). To overcome the reservation that the newly dividing cells
may not have been derived from the senescent population and in an effort to establish that escape
from TIS is feasible, tumor cells induced into senescence by chemotherapy were enriched for
senescence by flow cytometry; the subsequent division of senescent cells was demonstrable
utilizing both real-time, live microscopy and High Speed Live Cell Interferometry (HSLCI).
Furthermore, sorted senescent cells were observed to form tumors when implanted in immune
deficient mice and with a significant delay in immunecompetent mice. As chemotherapy induced
senescent cells have been identified in patient tumors, it is reasonable to propose that tumor cells
that escape from senescence could contribute to disease recurrence. In addition, therapy-induced
senescence could prove to reflect one form of tumor dormancy. Recently, ABT263 has been used
XVIII

as a senolytic drug, effectively eliminating senescent cells from aging-related animal models. Here,
we utilize ABT263 in a two-hit approach to eliminate senescent tumor cells that persistent after
exposure to chemotherapy. ABT263 results in the killing of senescent tumor cells in a
concentration-dependent manner and shifts the response towards apoptotic cell death.
Furthermore, sequential administration of ABT263 interferes with the ability of senescent tumor
cells to recover growth potential. These results indicate that senescent tumor cells can contribute
to cancer relapse by acquiring proliferative properties and that senolytic therapy allows for the
clearance of dormant senescent tumor cells and will potentially decrease cancer recurrence rates.

XIX

Chapter One: General Introduction

1.1. Historical Overview
The scientific perspectives on the replicative potential of cells in terms of cellular lifespan, aging
and cancer have changed dramatically during the last century. This work should contribute to
continuing efforts to understand the mechanisms that regulate stress, cell fate and responses to
cancer therapy.

1.1.1. Early Viewpoints on Cell Immortality
Although it is well-established that somatic cells have a limited lifespan, this was not the
predominant viewpoint on cultivated cells in the first half of the 20 th century (1). Instead, it was
thought that cells have the potential to divide indefinitely in culture, based in large part on the
work of Nobel Laureate Alexis Carrel (2). In 1912, Carrel was able to establish a chicken cardiac
fibroblast cell line in vitro that he and his colleague, Albert Ebeling, passaged in culture for more
than 10 years (3). Carrel and Ebeling claimed that cells are immortal when isolated and allowed to
grow under ideal culture conditions and that cellular aging was restricted to replicating cells in a
multicellular organism (4). This proposition influenced other aging biologists like Raymond Pearl,
who considered aging to be a process at the organismal level and thus, that cells can have an
unlimited lifespan when grown separately from the living organism (2). Despite the growing
consensus based on Carrel’s research evidence, there were no laboratories that succeeded in
growing cells indefinitely. For example, Haff and Swim attempted to grow rabbit cells in culture;
1

however, these cells died following 18 to 20 passages, a perplexing finding that was attributed to
extraneous factors and technical complications (2). Similar findings were considered as unusual
phenomena -- aberrations due to alteration in the cell culture media or confined to certain cell types
(2).

1.1.2. The Hayflick limit
This longstanding paradigm of vertebrate cells growing indefinitely in culture was finally proven
to be inaccurate in 1961 by Leonard Hayflick. Hayflick addressed this core issue by running a
series of cell cultivations of normal human fibroblasts to show that these cells have a finite cell
fate (5). For three years, Hayflick and his fellow Paul Morehead observed that fibroblasts
eventually ceased to divide when passaged multiple times (5). Of course, at the time, Hayflick
initiated these experiments with the mindset that Alexis Carrel was correct and hence, he was
concerned that a technical issue concerning the preparation of his culture medium or dishes was
the reason behind the inability of fibroblasts to continue dividing (6). To address this concern, he
designed a co-culture experiment of old male fibroblasts (doubled for 40 times previously) with
young female fibroblasts (doubled less than 10 times previously) (5). After a series of passages,
the cell culture was almost entirely occupied by only the female cells, indicating that the old male
cells had failed to continue proliferating (5). Certainly, this allowed Hayflick to confirm his
preliminary findings that cells only divided for a certain number of times and that an experimental
error was unlikely to account for his observation since the female cells were healthy and dividing.
Initially, Hayflick described different phases of the life of a dividing cell in culture and stated that
those which fail to proliferate after a number of doublings enter the phase III phenomenon 1 (5).

Phase I describes the initial culture, phase II describes doubling or proliferating cells while phase III describes
growth arrested cells.
1

2

More importantly, Hayflick demonstrated that cell aging is not a product of time, as cryogenically
preserved cells were able to divide normally even if kept frozen for years, indicating that cell aging
is encoded genetically (7).
It is worth mentioning that Hayflick and Morehead’s manuscript describing these findings was
rejected by the Journal of Experimental Medicine, the journal that published most of Carrel’s work,
when they attempted to publish their findings. The rejection was based on the fact that their
findings were not in line with the established dogma at the time (6). However, they succeeded in
publishing their first report in the Journal of Experimental Cell Research, which later became one
of the most highly cited papers in the history of modern science (5). Hayflick’s findings invited
other scientists to replicate the same findings and gradually a paradigm shift in cell biology took
place. After a decade, Australian Nobel Laureate Macfarlane Burnet used the expression “the
Hayflick limit” for the first time, which described the number of divisions a cell will undergo
before it ceases to divide (8). Finally, multiple theories have been proposed to explain the mystery
of Carrel’s cells that divided for 34 years including that these cells might have undergone a
replicative crisis or even transformation or perhaps were contaminated with an immortal cell line
(9).

1.1.3 Telomere dysfunction and telomerase
Although Hayflick’s findings were a breakthrough in cytogerontology, they were not explained
until later in the 1970s. In 1972, James Watson described a phenomenon called the “endreplication problem” where DNA polymerases are incapable of fully replicating the lagging strand
of a DNA double helix, always leaving a strip of unreplicated nucleotides at both ends of the linear
molecule (10). Accordingly, the DNA molecule undergoes gradual shortening every time the cell
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prepares to replicate its DNA in preparation for mitosis. This continuous attrition means that a
small stretch of the genetic material will be lost with successive divisions, providing the first
evidence that a deficiency in the DNA replication machinery could account for the inability of
cells to divide indefinitely. It was later revealed that the linear ends of eukaryotic DNA are capped
with short, repetitive sequences of nucleotides and that those “meaningless” repeats are lost as a
sacrifice for the end-replication problem (11). These DNA caps were termed telomeres and their
shortening eventually explained the inability of Hayflicks fibroblasts to continue dividing
indefinitely (12). Telomere shortening was subsequently discovered to occur in vivo in tissue
derived from aging humans (13).
The question that then comes to mind next is that of how immortal cells, such as pluripotent stem
cells and cancer cells can actually divide indefinitely? It was later determined that the enzyme,
telomerase is expressed in these cells and is responsible for elongating their telomeric ends (14,15).
In fact, telomerase was shown to be expressed in almost 90% of cancers (16). Telomerase, or
terminal transferase, is a reverse transcriptase enzyme that uses its own RNA template to elongate
telomeres, thereby solving the end-replication problem (17). It was later shown that stable
reintroduction of the telomerase catalytic subunit can stabilize the linear ends of normal human
cells and is sufficient to considerably prolong their life span or even to achieve immortality (18).
The identification of telomeres and telomeric dysfunction was essential to understand the Hayflick
limit. The telomeric ends of Hayflick’s fibroblasts were gradually being eroded every time
Hayflick passaged those cells and allowed them to divide. Consequently, we now fully understand
that persistent telomeric dysfunction in the absence of telomerase robustly activates the DNA
Damage Response (DDR) and leads to a stable, sustained growth arrested state routinely referred
to as cellular senescence (19). We also now know that the phase III phenomenon fibroblasts that
4

Hayflick described were in fact “senescent” fibroblasts and that the finite lifespan of somatic cells
is attributed to this one unique phenotype.

1.2 Cellular Senescence
1.2.1. The complexity of the definition
The word senescence is derived from the Latin word senex which refers to advanced age or an old
individual. Traditionally, the term cellular senescence was coined to describe cells that ceased to
divide following many doublings in vitro (7). However, gradually, the term took on further
dimensions to describe a more complex cellular phenotype. Initially, the definition established an
early and solid connection between the “old” or “aging” cells and their incapability to divide, in
that persistent “senescent” cells must be in a growth arrested state.

Furthermore, Hayflick

concluded very soon after his initial experiments that phase III phenomenon cells undergo
“irreversible functional decrements” that commit them into an “irreversible” cessation of growth
(20). Hence, cellular senescence not only describes a phase of growth arrest that results from
replicative exhaustion but that growth arrest must be permanent ـــــthe signature word in the
definition of cellular senescence is “irreversible”. Regardless of how a cell becomes senescent and
what biological alterations that change entails, the change must be irreversible, and a reversion to
the normal or pre-senescent stage is not feasible. It is difficult to pinpoint when exactly the
irreversibility of senescence became the most essential characteristic of the phenotype, but there
is a current overwhelming agreement that senescence describes an irreversible phenomenon and
that is how it is distinguished from other cell fates (21).
Despite the fact that our current understanding of cellular senescence extends beyond the growth
arrest described by Hayflick in the early 1960s, the insistence on the irreversibility of senescence
5

appears to be dogmatic. Judith Campisi, a lead scientist in gerontology and cancer research,
describes senescence as an “irreversible arrest of cell proliferation (growth) that occurs when cells
experience potentially oncogenic stress” (22). This definition was updated in 2016 but continued
to include irreversibility of growth arrest as a hallmark of the senescent phenotype (23). Many
others in the field seem to strongly agree. For example, Jerry Shay and Igor Roninson simply
define senescence as a “signal transduction program leading to irreversible cell cycle arrest” (24).
Clemens Schmitt refers to cellular senescence as an “irreversible cell-cycle arrest” which “reflects
a safeguard program that limits the proliferative capacity of the cell exposed to endogenous or
exogenous stress signals” (25). Collectively, these established opinions in the field place
irreversibility at the heart of the definition of cellular senescence.
On the other hand, despite this general agreement on the irreversibility of senescence, there has
been accumulating evidence that senescence might not be obligatorily a terminal cell fate. Drs.
Lynne Elmore and my adviser David Gewirtz together published observations suggestive of the
reversibility of senescence in tumor cells exposed to cancer chemotherapy, specifically
doxorubicin (26). It is noteworthy in this context that it has become well-established, as we will
discuss later in detail, that malignant cells retain the potential to undergo premature, or accelerated,
senescence in response to different forms of stress, such as that induced by cancer
chemotherapeutic drugs and radiation, which is the focus of this dissertation. Several laboratories
have either shown or suggested that senescence might be reversible, and that under certain
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Figure 1.1. Hallmarks of Senescence. Despite the fact that permeant growth arrest and failure of progression
through the cell cycle is the hallmark of senescent cells, the senescent phenotype encompasses a spectrum of
distinct features. Senescent cells have a characteristic morphology. They become large, flattened with abundant
cytoplasmic vesiculation. Senescent cells upregulate the lysosomal enzyme SA-β-gal. Cyclin-dependent kinases
(CDKs) are also upregulated. In addition to undergoing vast alterations in gene expression, senescent cells develop
also unique epigenetic changes collectively called the Senescence-associated heterochromatin foci (SAHF).
Senescence has been closely associated with polyploidy or multinucealtion. Finally and most importantly,
senescent cells engage into an active secretory process that involves the release of over 40 different cytokines,
chemokines and other mediators to their surroundings, a phenomenon called the Senescence Associated Secretory
Phenotype (SASP).

circumstances a cell can escape the permanent growth arrest after senescence induction, and that
the terminology of “irreversible” may not be accurate. During the American Association for
Cancer Research meeting in Chicago, Illinois in 2018, Rene Bernards, a prominent senescence
expert, has openly argued in a senescence discussion panel that the senescent growth arrest should
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Figure 1.2. Cell cycle: phases, checkpoints and regulation. A schematic diagram illustrating different phases
of the cell cycle. A cell spends the majority of its lifetime in the interphase (comprised of G 1, S and G2 phases)
before it prepares for mitosis and undergoes cell division (M phase). The progression through the cell cycle is
governed by cyclins and cyclin-dependent kinases which mediate necessary phosphorylation events that allow the
cell to transition through the next phase, such as the phosphorylation, and inactivation, of the retinoblastoma
protein Rb. The action of these proteins is opposed by cyclin-dependent kinase inhibitors. p53 is a transcription
factor that plays a major role in regulating the cell cycle and mediates the expression of p21 Cip1, a major cyclindependent kinase inhibitor. Several checkpoints ensure DNA integrity and monitor cellular size. If a cell is
subjected to lack of nutrition or scarcity of growth simulation it reversibly exits the cell cycle into G0 and becomes
quiescent, until favorable conditions are restored.

be more precisely described as “stable” rather than irreversible. However, this new description
connotes that the stability of senescence can be shaken. This new perception of what senescence
actually represents is a central focus of this dissertation. In a later section, we provide a detailed
analysis of some of the most important evidence in the literature that argues against the absolute
irreversibility of senescence.
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1.2.2. Features of the senescent phenotype.
Although a stable growth arrest is the hallmark of senescent cells, the senescent phenotype
encompasses a spectrum of distinct features. These features represent dramatic alteration in gene
expression that characterize the phenotype (Figure 1.1).

1.2.2.1 Growth arrest
When a mitotic cell is subjected to cellular stress, senescence is a potential outcome. The first sign
of senescence induction is failure of progression through the cell cycle (27). The cell cycle
describes a highly-organized sequence of events that lead to DNA replication and ultimately cell
division into two daughter cells. In eukaryotic cells, the cell cycle consists of four distinct phases,
in each of which the cell carries out specialized tasks (Figure 1.2). The M phase is the most
considerable phase of the cell cycle where the cell undergoes mitosis. However, it represents only
a short phase of the cell’s lifespan as the cell generally spends more time in the Interphase which
consists of G1, S and G2 phases. In G1, or gap-1, the cell engages in high metabolic activity where
it synthesizes a plethora of proteins and cellular suborganelles in preparation for the DNA
synthesis which takes place in S phase. After DNA replication is completed, the cell enters into
another gap phase, G2, where it continues to grow, this time in preparation for mitosis. Since the
cell undergoes DNA replication and doubles its chromosomal content in S phase, the DNA content
varies from one phase of the cycle to another. For example, in G1, and prior to DNA replication,
the cell contains a diploid number of chromosomes (2n), while in G2, after DNA replication the
chromosomal number is doubled (4n).
Depending on the stimulus, cell type and which face of the cell cycle the cell is circulating in at
the moment of stress, a senescent cell can have variable DNA content. Classically, human
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fibroblasts undergoing telomeric dysfunction senesce with a G1 DNA content (28). However, due
to certain derangements in cellular stress response pathways, a human fibroblast can senescence
with a G2 DNA content as well (29). Similarly, a fibroblast accumulating oncogenic mutations can
senesce with a G2 DNA content (30). Moreover, tumor cells driven into extensive genomic
instability induced by exposure to DNA damaging therapy often undergo a G2-M growth arrest
(31).
Progression through the cell cycle is tightly controlled by internal regulatory mechanisms and in
response to critical extracellular stimuli. These stimuli are often growth signals that encourage the
cell to continue proliferating. The main drivers of the cell through the cell cycle are
serine/threonine protein kinases that are collectively called cyclin-dependent kinases (CDKs). The
reason for the terminology is that these kinases depend on their activity on the binding of another
group of proteins called cyclins. The third line of regulatory machines are called cyclin-dependent
kinase inhibitors (CDKIs) which, as the name indicates, inhibit the necessary phosphorylation
events carried out by CDKs, and thus, put brakes on further progression through the cell cycle.
Several checkpoints monitor key process throughout the cell cycle such as cellular size (protein
content and geometry), DNA replication, the lack of DNA damage and the integrity of the
replisome and the mitotic spindle during division. These checkpoints are controlled by a
complicated network of pathways that can enforce cell cycle arrest if a threatening defect (e.g.,
considerable DNA damage) occurs.
CDKIs play the main role in regulating the growth arrest of senescence, and are therefore, used as
markers for senescence induction both in vitro and in vivo (32). In fact, the ectopic expression of
these CDKIs, such as p16INK4a and p21Cip1, on their own, can result in the induction of senescence
(33). The role of these proteins in the induction and maintenance of senescence is indispensable,
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although senescence can still be induced in the absence of particular CDKIs, for example, in tumor
cells that suppress the expression of p16INK4a during transformation but retain the potential to
undergo accelerated senescence.
p16INK4a, encoded in the CDKN2A gene, is a tumor suppressor and a CDKI that is closely
associated with the senescent phenotype (34). In fact, p16INK4a accumulates in the tissue of aging
individuals, both in mice and humans (35,36). Moreover, p16INK4a is induced in tissues exposed to
ionizing radiation in parallel with the accumulation of senescent cells (37). As the cell progresses
through G1, cyclin D levels gradually increase so that it starts binding to the available CDK4 and
CDK6, initiating a cascade of phosphorylation events that include the phosphorylation of the
retinoblastoma protein (Rb). Rb phosphorylation (pRb) inactivates the protein, leading to the
release of the transcription factor E2F which promotes the transcription of many genes necessary
for progression from G1 to S. p16INK4a is often expressed late in response to telomeric or
intrachromosomal DNA damage but leads to a robust inhibition of the CDK 4/6 and any further
progression through G1 through the hypophosphorylation (or the dephosphorylation) of Rb) (38).
Finally, p16INK4a expression is regulated by the binding of several transcription factors to the
CDKN2A promoter, including PPARγ, AP1 and Sp1. (39,40). Furthermore, other epigenetic
modulations such as demythelation of the CDKN2A promoter can also result in p16INK4a and
senescence induction (41).
p16INK4a expression is often suppressed in many pre-malignant or malignant cells (42,43). For
example, the majority of pancreatic malignant cells lose the function of p16INK4a by the time they
are fully transformed (44). In fact, p16INK4a mutations often occur early during transformation and
result in the loss of an important barrier against cancer development (45,46). Despite the essential
role of p16INK4a in implementing the stable growth arrest of senescence, especially in aging
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fibroblasts, mutational deletion of p16INK4a or suppression of its expression by methylation in
tumor cells does not actually mean that these cells will fail to undergo senescence in response to
cellular stress; in fact many tumor cells retain the potential to undergo senescence in response to
DNA damaging therapy (47). Indeed, this adds another factor of complexity to the senescence
phenotype, as the absence of p16INK4a might affect the stability of senescent tumor cells especially
that it has been described to be a regulator of late maintenance of the cell cycle arrest rather than
its induction (48).
p21Cip1 is another important CDKI that regulates the senescent growth arrest (49). p21Cip1 is
capable of inhibiting multiple cyclins/CDKs complexes, thereby resulting in a growth arrest at
different phases of the cell cycle. Despite its strong association with senescence, p21Cip1 is not
considered sufficiently unique (in fact none of the senescence markers are) to solely describe the
induction of senescence. For example, p21Cip1 can be induced during quiescence due to scarcity of
growth factors (50). However, there is an extensive body of literature suggesting its essential role
in senescence induction in tumor cells in response to DNA damaging therapy, especially since
p21Cip1 is directly induced by p53 as part of the response to DNA damage (47). In fact, recent
evidence has suggested that p21Cip1 is essential for the maintenance of the senescence phenotype
by restraining pro-cell death pathways (51). Furthermore, p21Cip1 is responsible for regulating the
response to DNA damage in senescent cells and its absence (e.g., by genetic knockdown) shifts
the response to cellular stress towards apoptosis (51). In addition, deletion of the CDKN1A locus
which encodes for p21Cip1 extends the lifespan of mice with dysfunctional telomeres, possibly due
to the reduction in the number of accumulating senescent cells (52). Ultimately, p21Cip1 is a pivotal
component of the senescent phenotype.
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Finally, other CDKIs can potentially make substantial contributions to the induction and/or
maintenance of senescence. For example, p27Kip1 is necessary for pRb-mediated senescence
through the binding and inhibition of cyclin E-associated kinases in osteosarcoma cells (53), and
p15INK4b is known to accumulate in senescent T lymphocytes (54).

1.2.2.2 p53 and the activation of the DNA damage response
In the majority of cases, senescence is a direct consequence of severe DNA damage and persistent
activation of the DNA damage response (DDR) (55). The DDR describes an integrated signaling
pathway that detects DNA lesions and promotes their repair (56). The basic function of the DDR
is to enforce cell cycle arrest until the defects in the DNA are repaired, after which the cell can
resume proliferating. In senescence, severe DNA damage appears to induce a stable DDR and a
more stable growth arrest. The DDR is a consequence of a variety of senescence-causing DNA
damage events, including the classical telomere dysfunction in aging cells (57), exposure to
genotoxic chemotherapeutics or radiation (58) as well as in cases of hyperreplication resulting
from oncogene overexpression (30). While the DDR represents the first initiating event in the
induction of senescence, and is therefore considered to diminish over time after the phenotype is
established (59), recent evidence has suggested that the DDR is stably associated with senescence
(55).
Large protein kinases, ataxia-telangiectasia mutant (ATM) and ataxia telangiectasia and Rad3
related (ATR), are activated by DNA damage; both proteins are recruited to the sites of DNA
double-stranded breaks (Figure 1.3) (60). Once activated, ATM carries out a cascade of
phosphorylation events, including the activation of the checkpoint kinase 2 (Chk2), and
subsequently, increased transcription of p53 (60). Subsequently, p53 induces the expression of
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Figure 1.3. Regulatory pathways of cellular senescence. Regulation of cellular senescence is a complex and not
completely understood process that involves the interaction of several pathways. Several cellular stresses result in
the he induction senescence, most importantly, unrepaired DNA damage. DNA damage results in the activation
of ATM and CHK2 of the DDR, followed by the activation of p53ــــp21Cip1 axis resulting in the Rb
hypophosphorylation and activation, preventing progression into S phase The activation of p16INK4a (and
subsequent Rb hypophosphorylation) is an essential component in the maintenance of the senescent growth arrest.
p16INK4a is often mutated and inactivated in many tumor cells. Despite the stressed mitochondria, antiapoptotic
factors of the Bcl-2 family stabilize the mitochondrial membrane and facilitate resistance to apoptosis. ATM and
other regulators of the DDR contribute to the SASP. However, p38MAPK has been shown to control SASP
independently of the DDR explaining the delayed induction of the secretory phase. p38MAPK is another key
regulator of maintaining the senescent phenotype (promotes p53 and p16 INK4a activation) and its inhibition (or
knockdown) is suspected to accelerate the capacity of cells to recover from senescence. Cellular stress can also
result in mTOR (TORC1) activation which is involved in enhancing protein translation. Ultimately, multiple
secretory factors (chemokines, cytokines, growth factors, structural proteins, etc) are secreted to the surroundings.
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p21Cip1 which in turn inhibits the activity of cyclin-dependent kinases and results in growth arrest
(47). At the same time as the cell undergoes cell cycle arrest, ATM activates repair mechanisms
by recruiting multiple repair-associated factors to the damaged sites, primarily by the
phosphorylation of the histone H2AX (γH2AX) which serves as a point of assembly of many of
these repair complexes (60). The importance of the DDR in senescence induction is reflected by
studies where its components have been disabled, which resulted in attenuation of senescence
induction. For example, knockout of ATM in mice reduced the diabetes-associated accumulation
of senescent endothelial cells in their main arteries (61), while ATM knockdown in breast tumor
cells reduced the percentage of cells that undergo senescence in response to adriamycin genotoxic
stress (62).
p53 plays a unique role in the regulation of the senescence phenotype (63). As discussed above,
through its action as a transcription factor, p53 is able to induce the expression of CDKIs that
mediate the senescence-associated growth arrest. Apart from its classical role in DNA damage
repair, p53 exerts its tumor suppressive function via senescence induction in response to oncogenic
stimulation (64). Accordingly, loss of p53 activity in Ras-overexpressing mouse embryonic cells
allows them to bypass senescence induction (64). Mammary epithelial cells in mice where Ras is
experimentally over-induced can develop cellular senescence as a barrier against transformation;
however, in the case of p53 ablation, these cells can progress to generate hyperplastic lesions that
can develop into tumors (65). In tumor cells exposed to DNA damaging therapy, p53 appears to
be essential for senescence induction as tumor cell lines harboring mutant p53 failed to become
senescent and underwent apoptotic cell death or mitotic catastrophe in response to the genotoxic
stress (31). As part of the research in our group, we have shown that MCF7 breast tumor cells with
silenced p53 fail to undergo senescence in response to adriamycin exposure (66). Breast tumor
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samples from patients that have been exposed to cycles of chemotherapy show the accumulation
of senescent cells that also show increased p53 staining (58). This important observation has also
been described by our group (shown below). Despite this strong association between p53 and
senescence, paradoxical evidence has been proposed where p53 is found to suppress the
senescence program in cases where a cell is undergoing conventional growth arrest or quiescence,
indicating the complexity of p53’s role in senescence regulation (67). In those lines, the kinetics
of p53 activation appears to play a role in determining cell fate in response to stress, i.e., whether
the cell will undergo senescence or other forms of cell death (68). p53 is also implicated in several
gene expression alterations, including the expression of many senescence-associated secretory
factors which we discuss further below. Thus, p53’s contribution to senescence extends beyond its
original activation as a component of the DDR.

1.2.2.3 Resistance to apoptosis.
Apoptosis is the most studied cell stress response, describing a programmed cascade of cellular
events that culminate in cell demise. Physiologically, just like senescence, apoptosis is a tumor
suppressor mechanism that eliminates potentially cancerous cells; however, the difference is that
apoptotic cells are cleared while senescent cells persist. In fact, senescent cells are by definition
resistant to apoptosis (cell death). For example, human fibroblasts induced into senescence by
oxidative stress can survive in culture despite death-inducing growth factor deprivation which was
later attributed to the absence of nuclear insulin-like growth factor binding protein-3 (IGFBP3)
(69). Senescent cells can also downregulate the expression of necessary apoptosis executioners
such as caspase-3 or death-associated protein 3 (DAP3) (70–72). More importantly, senescent cells
overexpress antiapoptotic proteins such as members of the Bcl-2 family shifting the balance
towards survival (73). Senescent human fibroblasts fail to downregulate Bcl-2 in response to
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death-inducing stimuli due to constant c-AMP/CREB stimulation, a pathway that positively
regulates Bcl-2 (74). It is also evident that senescent cells upregulate other antiapoptotic members
of the Bcl-2 family such as Bcl-w and BclXL (75,76). Despite these different explanations of how
senescent cells resist apoptosis, the exact mechanism is still poorly understood, especially since
non-senescent growth arrested cells can also exhibit apoptosis-evading behavior (77). Overall,
resistance to apoptosis is one quality that explains how senescent cells remain stable in culture for
prolonged periods of time and possibly persist in viable tissues.

1.2.2.4 Enhanced lysosomal biogenesis
Senescent cells remain metabolically active and undergo changes at the levels of subcellular
compartments. A primary feature of senescent cells is the increase in lysosomal mass, an
observation evident by the remarkable enhancement of acidic vesicles staining in senescent cells
(78). Moreover, this accumulation of lysosomes or lysosomal dysfunction is a feature of aging
tissue (79). This phenomenon has been tightly linked to senescence following the identification of
increased expression of the lysosomal β-galactosidase enzyme by Dimri et al (80). The enzymatic
activity of this enzyme is distinct in senescent cells as this lysosomal enzyme remains functional
at unusually high pH condition (~pH=6). The Senescence-Associated β-galactosidase (SA- β-gal)
enzyme is not detectable in quiescent or terminally differentiated cells as demonstrated by Dimri
et al (80). The origin of the upregulation in SA- β-gal function comes from GLB1, which is the
gene encoding for the lysosomal beta-D-galactosidase (81). Unlike SA- β-gal, the activity of βD-galactosidase is typically detected at ideal lysosomal pH (~pH=4.5). Cells with depleted GLB1
mRNA fail to express SA- β-gal despite undergoing senescent-growth arrest after replicative
exhaustion (81) . Thus, SA- β-gal reflects the upregulation in lysosomal activity which is probably
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a consequence to the accumulation of damaged organelles which frequently occurs in senescent
cells.

1.2.2.5 Gene expression alteration and the senescence-associated
secretory phenotype
Senescent cells undergo extensive alterations in gene expression (82), changes that are not
confined solely to genes involved in cell cycle regulation, but also include increased expression of
a spectrum of secreted proteins (83,84). Specifically, senescent cells have been reported to secrete
a spectrum of pro-inflammatory chemokines and cytokines that have paracrine tumor stimulatory
effects (84) contributing to metastatic progression and age-related diseases even in younger cancer
survivors (85).
The Senescence-associated Secretory Phenotype (SASP) can be a direct consequence of the
activation of the DDR which is uniformly induced in tumor cells treated with chemotherapy or
radiation (86,87) and can also result from oncogene-overexpression and hyper DNA replication
(30). As discussed above, interference with DDR-associated proteins such as ATM or Chk2
attenuates the senescent response (62,86). p53 is not only a regulator of the senescent growth arrest
but also partake in gene expression regulation of senescence. (88). While p53 is not an absolute
requirement for cells to undergo senescence, loss of p53 function in senescent cells might actually
facilitate recovery from senescence (89–91). This is particularly important given the fact that many
tumor cells have mutations that affect the function of p53 (92). Conversely, loss of p53 function
can result in enhanced SASP and its ability to drive pro-tumorigenic proliferation (93). The role
of p53 in SASP regulation is further shown in senescent hepatic stellate cells implicated in hepatic
cirrhosis where p53 ablation attenuates the inflammatory drive mediated by SASP (94). However,
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the SASP can be precipitated independently of DDR, such as in the case of senescent cells that
develop non-pathologically during embryogenesis (95) or during wound healing (96).
Interestingly, SASP induced by wound healing after mechanical injury lacks IL-6, bFGF and TGFβ expression (96), whereas several of these factors are expressed after exposure of the lung to DDR
inducing chemicals (97), or from DDR-inducing CYR61 exposure to fibroblasts (98). These
observations demonstrate that the composition of the SASP can vary considerable depending on
how the senescence is induced.
In addition to DDR and its signaling pathways, cell cycle regulators play important roles in
regulating the SASP. Despite the fact that many tumor cells lose p16INK4a function during
transformation, they retain the ability to develop the SASP upon DNA damage, most likely
because SASP is regulated independently of cell cycle arrest (33,99). This dissociation between
SASP and cell cycle regulators is also true for p21Cip1 (33), although in certain scenarios where
SASP is induced independently of DNA damage, p21Cip1 knockdown can attenuate the secretory
response (95).
The SASP is further regulated by p38MAPK which, in addition to p53 and p16INK4a activation, is
responsible for an increase in the activity of NF-κB (100). p38MAPK is a primary responder to
cellular stress and is activated in response to a variety of antitumor agents (101), while NF-κB is
responsible for the transcriptional activation of many SASP components and is a chief regulator
of TIS (102). In addition to NF-κB, the C/EBPβ transcription factor is necessary for the
development of oncogene-induced senescence (OIS) in primary fibroblasts (103). The interplay
between C/EBPβ and its heterodimeric partner C/EBPγ regulates the expression of multiple SASP
genes (104). Lastly, mTOR appears to play a critical role in the regulation of the SASP as
rapamycin promotes a robust suppression of inflammatory mediator release (105). In fact, mTOR
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inhibition selectively inhibits the translation of the membrane-bound cytokine IL1α, resulting in
decreased NF-κB-driven expression of multiple SASP factors (106).
While senescence and SASP are consistently observed in the laboratory in cancer cells both in
vitro an in vivo as a response to DNA damaging agents (107–109), certain targeted therapies can
also induce senescence in tumor cells. For example, the anti-VEGF drug bevacizumab (or
inhibition of the VEGFR2 pathway) was able to induce a modest senescent response in colon
cancer cells, xenografts, as well as patients’ tumors in a p16INK4a dependent manner (110,111). In
this study, senescence was evaluated based on SA-β-galactosidase staining and p16INK4a
expression; however, the ability of bevacizumab to induce SASP expression was not investigated.
The effects of anti-VEGF agents on senescent tumor cells are interesting, since VEGF is a core
element of the SASP. In fact, bevacizumab in combination with chemotherapy was associated with
improved clinical outcomes in glioblastoma patients (112). However, it is not known whether this
effect was attributed to enhanced senescence or due to blockade of VEGF as a SASP component.
Recently, aurora kinase inhibitors were shown to induce a robust senescent response in chronic
myeloid leukemia, melanoma and non-small cell lung cancer cells (113,114). Moreover, CDK4/6
inhibitors such as palbociclib have also been shown to induce a pronounced senescence response
in triple-negative breast cancer cells (115). While it is not certain if palbociclib can drive a
secretory response in these senescent tumor cells, it was shown that chronic palbociclib treatment
promotes senescence and a robust SASP in melanoma-associated fibroblasts which results in
enhanced growth of multiple melanoma cell lines (116). This observation is particularly important,
since CDK4/6 inhibition is not traditionally associated with DNA damage per se, suggesting a
possibility for inducing SASP by alternative pathways (in this context, palbociclib has been shown
to interfere with DNA damage repair only when tumor cells are exposed to radiotherapy (117)).
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Finally, multiple SASP factors do appear to have the potential to fortify the senescent phenotype
in a self-reinforcing autocrine fashion. For example, the chemokines receptor CXCR2 (IL8RB)
closes the circuit of senescence induced by DNA-damage as it conveys NF-κB activation signals
by multiple CXCR2-binding factors (118). Furthermore, as a component of the increased
expression and release of multiple inflammatory mediators, senescent cells with activated mTOR
can actually also show enhanced expression of cytokine receptors such as soluble IL-6R,
supporting the premise that the tumor cells could be amenable to self-stimulation (119).
Plasminogen activator inhibitor-1 is also a pivotal SASP component that is necessary for the
induction and maintenance of the senescent phenotype in fibroblasts (120).
Despite the extensive body of literature relating to the SASP, it is uncertain whether the SASP
contributes to the maintenance of senescence or promotes escape from senescence. In fact, the
dynamic interplay of the different regulatory pathways of SASP can yield different functional
outcomes. For example, the oscillation of NOTCH1 expression and signaling during transition into
OIS can culminate into two distinct SASP profiles with variable effects (either an antiinflammatory TGF-β or a pro-inflammatory SASP response) (121). To summarize, the outcome
of the SASP is dependent on the heterogeneity of the senescent response (75), the profile of
secreted factors dictated by the interplay of the SASP’s regulatory pathways, cell type, temporal
status of senescence and interaction with other components of the microenvironment (122).

1.2.2.5 Structural and morphological changes.
Senescent cells develop distinct morphological changes characterized by enlarged cellular size and
flattening (123). These cells reach a critical cell mass beyond the point where cells usually undergo
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mitosis. This is largely due to the activation of the mTOR pathway 2 and enhanced ribosomal
protein biogenesis which is often seen in enlarged senescent endothelial cells (124). Also,
senescent cells undergo dramatic changes in the cytoskeleton which account for the neuronal-like
morphology of their cell bodies, an alteration dictated by ATF6α signaling pathway3 (125). This
change consists of dynamic structural rearrangements in the vimentin filaments which also
undergo unique posttranslational oxidation that is specifically expressed in senescent fibroblasts
(126). Furthermore, the composition of the plasma membrane in senescent cells is altered,
acquiring increased caveolin-1 content, which is part of the caveolae cholesterol domains 4 (127).
Senescent cells also exhibit changes in the nuclear structure. For example, irradiated human
fibroblasts that express SA-β-gal and growth arrest (but not SASP), have a reduced DNA content
quite similar to pre-apoptotic cells, yet not sufficient to induce cell death (128). In addition, the
nuclear lamina, a delicate meshwork lining the nucleoplasmic side of the nuclear envelope,
undergoes characteristic changes during senescence (129). These changes include the formation
of interaction points between damaged DNA foci and certain components of the lamina resulting
in changes in the spatial organization of the nucleus (129). These interactions were found to play
a pivotal regulatory role in senescence by controlling the expression of the repositioned genes
(130). Furthermore, the nuclear periphery serves as a deck for the sequestration of many
cytoplasmic proteins which might be related to derangements in the lamin protein family (131).
Lamin B1, an essential component of the nuclear lamina, is downregulated in senescent cells,
resulting in nuclear instability and chromosomal fragmentation (132). Lamin B1 loss occurs in

The mTOR pathway is involved in regulating several cellular processes including protein synthesis. mTOR
activation has been shown to be critical for establishing senescence.
3
ATF6α is an endoplasmic reticulum-associated transcription factor that is induced in response to cellular stress as
part of the misfolded protein response.
4
Caveolae are cholesterol-rich protein domains that are important component of cellular membranes of many cell
types and play a critical role in extracellular signaling.
2
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cells induced into senescence by replicative exhaustion or oncogene overstimulation, suggesting
its universality as a senescence feature (132). Lamin B1 loss appears to be regulated primarily by
the p53/p21Cip1 and p16INK4a/pRB pathways, but not p38MAPK or oxidative stress pathway (132).
In addition to laminar changes, senescent cells exhibit dynamic alterations in the chromatin
structure. In eukaryotic cells, chromatin is folded into a loose, less compact euchromatin, which
permits active transcription of many genes, and a more condensed, closed heterochromatin, which
is associated with a lower transcriptional drive (133). For example, when the cell decides to
decrease the expression of a certain gene, the chromatin spatially reorganizes into heterochromatin
which is thought to prevent the access of essential transcription factors, and thus, silencing of the
gene (134). Senescent cells develop similar changes in their nuclei and develop what is collectively
referred to as the Senescence-Associated Heterochromatin Foci (SAHF). This unique association
of chromatic changes with senescence was first reported by Scott Lowe’s group (135). Narita et al
demonstrated that these foci of condensed chromatin are rich in characteristic histone
modifications such as the heterochromatin protein (HP1γ) and histone H3 trimethylation on lysine
9 (H3K9Me3) (135). Furthermore, they demonstrated that these foci represent areas of repressed
gene expression, in particular, genes regulated by the transcription factors E2F, thus linking the
development of SAHF to the Rb pathway (135). In other words, upon senescence induction and
activation of RB (hypophosphorylation of Rb), the chromatin condenses in regions containing
genes associated with cell proliferation, preventing their expression, which is mediated by E2F.
Hence, these changes are not strictly structural but appear to play an important regulatory role.
Senescent WI38 fibroblasts undergoing oncogene-induced senescence and expression of SAHF
including H3K9Me3 and H1Pα, β and γ, also contain the transcriptionally repressive variant of
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histone H2A, macroH2A (136). SAHF can also contain other histone markers such as H4K20Me3
and a unique peripheral localization of H3K27Me3 at the nuclear rim (137,138).
In addition to the changes to the plasma membrane, nucleus and lysosomes, senescent cells also
accumulate mitochondria. In fact, a major component of the accumulating dysfunctional organelles
in aging cells are mitochondria with deranged membrane integrity (139). This probably happens
due to a dysfunctional autophagic response occurring as part of the senescent phenotype; however,
the connection between senescence and autophagy is not fully understood and is discussed later
on (140). Overall, the increase in mitochondrial fusion and disrupted mitochondrial membrane
potential contributes to the accentuated oxidative stress that accompanies senescence and possibly
contributes to the stability of the growth arrest (139). This abnormal accumulation of mitochondria
has been reported in many senescent cell types and in response to several senescence inducing
stresses and is now collectively referred to as the Senescence-Associated Mitochondrial
Dysfunction (SAMD) and as an additional feature of the phenotype (141).

1.2.4. Types of senescence
Senescence is classified into multiple types based primarily on the type of stressor. Senescence
can be induced by a variety of stressful stimuli, including DNA damaging agents, which has been
a focus of our work.

1.2.4.1 Replicative Senescence.
Replicative senescence is the well-established form of cellular senescence which was originally
described by Hayflick (7). Replicative senescence is a primary cellular mechanism of aging and
reflects the finite capability of a cell to proliferate. As mentioned earlier, replicative senescence is
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the product of progressive telomere attrition (often described as telomere dysfunction) that occurs
as a consequence of the end-replication problem (10,12). Telomeres are DNA segments that cap
the linear ends of the DNA and consist of repetitive, meaningless stretches of nucleotides (17). In
the non-replicating chromosome, telomeres arrange in a loop-like structure called the T-loop, in
association with the DNA protective proteins, shelterins (142). Due to the end replication problem,
which results from inability of DNA polymerase to replicate the end of the lagging strand, the
telomeric length is shortened by around 150 bases with each cell division. Interestingly, the length
of telomeres varies within the same cell, and the critical shortening of only one or two telomeres,
rather than the average telomeric length, is sufficient to induce chromosomal instability (143).
The exact number of divisions that a cell can undergo varies between different cell types; however,
once the telomeres reach a critical length, the resulting dysfunction triggers the DDR (144). This
involves the phosphorylation of ATM and ATR with subsequent activation of p53 and other
associated proteins, ultimately inducing senescence. The reason behind why cells respond to
telomere dysfunction and activation of DDR with senescence rather than apoptosis is still poorly
understood; however, this reiterates the fact that senescence is a response to genomic instability.
In all cases, telomere shortening is not an unsolvable problem. Telomeres can be elongated by the
reverse transcriptase, telomerase (18). However, most somatic cells do not express this enzyme
and thus remain bound to a limited lifespan and undergo replicative senescence. While telomerase
expression can successfully delay or bypass the onset of replicative senescence, it does not seem
to affect senescence precipitated by non-telomeric DNA damage (66,145). Collectively, replicative
senescence describes a stress response to telomeric DNA damage resulting in a stable growth
abrogation in proliferating somatic cells and represents a fundamental basis of cellular and
organismal aging.
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1.2.4.2 Oncogene-induced senescence.
Oncogenes are mutated genes that can drive the transformation of a cell to become cancerous.
Evolutionarily, several defense mechanisms have developed to combat the overexpression of
oncogenes and prevent cancer occurrence. Interestingly, many cells also develop senescence as a
response to oncogene overexpression. The first observation of oncogene-induced senescence was
made in Scott Lowe’s laboratory, where his group showed that fibroblasts expressing mutant Ras,
a mitogenic signal transducer, undergo cellular senescence characterized by a permanent G 1
growth arrest (64). This form of senescence had similar features to replicative senescence and was
regulated by p53 and p16INK4a (64). However, it was not associated with telomere shortening or
limited replicative potential of the fibroblasts, and thus was described as a premature, or
accelerated form of senescence. Sequentially, oncogene-induced senescence was described to
occur in response to multiple pro-proliferative oncogenes such as Raf and E2F-1 (146,147).
Furthermore, senescence can also be induced by the loss of certain tumor suppressor genes, such
as PTEN, representing a barrier against neoplastic potential (148).
This role of senescence in combating events leading to neoplastic transformation such as oncogene
overexpression or tumor suppressor gene suppression set the evolutionary significance of
senescence as a vital tumor suppressive mechanism (149). If fact, senescent cells accumulate in
premalignant lesions, possibly as a first barrier to acute oncogenic aberrations (150). The classical
example is the identification of senescence markers in naevi containing BRAF overexpressing
melanocytes (151). In most cases, senescence is sufficient to block oncogenic transformation and
results in a permanent abrogation of growth of a cell harboring an active oncogene; thus, bypassing
oncogene-induced senescence is essential for malignant transformation. Accordingly, the coexpression of an additional oncogene, or a “second hit”, is required for a cell to overcome the
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oncogene-induced senescence and proceed towards becoming cancer (152). Finally, it is important
to mention that oncogene-induced senescence is in fact a product of the activation of the DDR
resulting from genomic instability induced by DNA excessive replication, which occurs as a result
of oncogene-driven increase in cell proliferation (30). This again reiterates that senescence is a
consistent cell response to oncogenic genomic alteration where its main role is to oppose malignant
transformation as a failsafe tumor suppressor mechanism.

1.2.4.3 Therapy-induced senescence.
Early on, it was unexpected that tumor cells would undergo terminal senescence since they are
immortal and possess the ability to divide indefinitely, at least in cell culture. This immortality is
based, although not fully, on the fact that most tumor cells re-express telomerase which
theoretically allows for an unlimited number of cell divisions by preventing telomeric dysfunction.
However, the first clue that senescence induction is still feasible in immortal tumor cells originated
from studies where human diploid fibroblasts underwent senescence due to non-telomeric DNA
damage (153). This observation suggested that inflicting DNA damage in a tumor cell might
induce a senescence-like phenotype. Early studies attempting to induce senescence in tumor cells
utilized somatic fusion approaches where nuclei of normal cells were fused in tumor cells and
resulted in growth arrest (154). These experiments suggested that the senescence genetic program
is dominant and can be re-established even in immortal tumor cells. These studies were followed
by a more focused examination of the role of certain senescence-associated genes in inducing the
phenotype in tumor cells. For example, the re-induction of p53 expression in EJ bladder carcinoma
cells that lack p53 resulted in immediate induction of p21Cip1, subsequent G1/G2-M irreversible
growth arrest as well as increased SA-β-gal expression (155). Using an inducible gene expression
system, expressing functional Rb protein in Rb-defective breast, osteosarcoma and bladder tumor
27

cells resulted in a stable G1 growth arrest and the induction of several other senescence-like
features (156). Overexpression of p21Cip1 in H1299 p53-deficient lung tumor cells results in an
irreversible growth arrest and the induction of multiple feature of senescence (157). These
experiments further elucidated the pivotal role of these proteins in the induction and maintenance
of senescence, but more importantly, demonstrated that senescence can still be induced in immortal
tumor cells.
The first evidence of the ability of tumor cells to senesce in response to cancer chemotherapeutics
was presented in nasopharyngeal carcinoma cells (CNE1 cell line) in response to the DNAcrosslinking agent cisplatin (158).

After exposure to cisplatin, these cells demonstrated

morphological changes consistent with senescence, underwent a stable growth arrest and
expressed SA-β-gal and this resulting state was termed “senescence-like” phenotype since it was
not precipitated by aging or inhibition of telomerase (158). Further studies on chemotherapyinduced senescence in tumor cells were published by the Igor Roninson group (31). In those
studies, Chang et al performed an initial screen of the ability of several chemotherapeutic agents
to induce senescence in 14 cancer cell lines based on SA-β-gal expression and the induction of
growth arrest (31). At subtoxic concentrations, many of these drugs resulted in SA-β-gal
expression and growth arrest in these cell lines, with topoisomerase inhibitors, such as
doxorubicin, producing the strongest effect, and with microtubule poisons being the weakest (31).
Soon after, multiple laboratories have shown the induction of senescence in multiple tumor cell
lines in response to a wide variety of anticancer drugs such as etoposide, hydroxyurea, and
camptothecin (159). Our laboratory has established that the induction of senescence in tumor cells
by doxorubicin was independent of telomere dysfunction and was not affected by telomerase
expression unlike the case in replicative senescence (66). Chemotherapy-induced senescence in
28

tumor cells was also associated with a robust secretory phenotype (160,161). Interestingly,
senescence was also induced in tumor cells exposed to non-DNA damaging agents such as the
growth factor, TGFβ, or retinoids (162,163). Similar to human or mouse fibroblasts, exposure of
tumor cells to ionizing radiation results in accelerated senescence (164). In fact, tumor cells
respond much faster and to lower doses of radiation in comparison with non-transformed
fibroblasts, perhaps because of a higher susceptibility of tumor cells to radiation induced DNA
damage. Lastly, it was established that senescence represents a fundamental response to DNA
damaging anticancer therapy in vivo in cancer patients exposed to neoadjuvant cancer therapy
(doxorubicin, cyclophosphamide and 5-fluorouracil) (58,165).

It is now well-established that exposure to a variety of cancer therapeutics or radiation precipitate
senescence in tumor cells, and that senescence is a primary component of the outcome of these
therapies (166). The senescent response is not limited to conventional DNA damaging agents, but
can also be induced by several targeted cancer therapies such as the CDK inhibitor palbociclib
(116,117), aurora kinase inhibitors (113,114) and epidermal growth factor receptor inhibitors
(167). Therapy-Induced Senescence (TIS) also contributes to the effectiveness of cancer treatment
and represents an important prognostic factor (168). Due to its importance in dictating therapeutic
outcomes, TIS is the main focus of this dissertation.

1.3 Senescence vs. quiescence
Since both, senescence and quiescence, describe states of cell cycle arrests, it is quite important to
discuss the major differences between the two phenotypes. In addition, there is a great confusion
in the literature based on experimental findings where cells exposed to cellular stress undergo a
transient growth arrest, are strictly defined as quiescent. The reason is that quiescence classically
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describes a state of transient, reversible growth arrest where cells arrest temporarily with a G 1
DNA content (referred to as G0 phase, Figure 2) to resume proliferation when favorable conditions
are restored (169). The less durable nature of the quiescent growth arrest represents the major
feature to be taken in consideration in making a distinction between senescence and quiescence.
However, the complexity of both phenotypes extends beyond the stability of the growth arrest. For
example, quiescence is often induced by stress stimuli that differ from senescence-triggering
factors (discussed above). Such stimuli include primarily mitogenic deprivation or lack of growth
factor stimulation, something that senescence appears to be independent of (170). Furthermore,
cells can undergo quiescence as a results of over-confluence and the resulting contact inhibition or
from loss of adhesion (171). Senescence on the other hand is tightly linked to oncogenic genomic
instability. Thus, the mechanisms by which both phenotypes are induced are remarkably different.
For sure, the quiescent growth arrest requires regulation by CDKI and it is true that p21 Cip1
accumulates in quiescent cells; however, it has been recently proposed that p21Cip1 is more
important in inducing a more durable growth arrest, which often is associated with senescence
(169). Moreover, p16INK4a appears to play no or minimal roles in quiescence in comparison to its
exceptional importance in maintain the hypophosphorylation of Rb in senescent cells, and thus,
the stability of the growth arrest (172). G0 is not just an extended phase G1. Major changes in genes
expression distinguish quiescent cells from proliferating cells, or even, from senescent cells (173).
Furthermore, quiescent cells, due mostly to lack of proliferative stimulation, reduce their metabolic
drive, very often reflected by a decrease in mRNA translation (174) (although this has been
controversial since several provocative reports have shown that quiescent cells are metabolically
active (175)). However, senescent cells are metabolically active and maintain active protein
synthesis which results in the secretion of several proteins as part of the SASP (176). Lastly,
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senescent cells possess a distinct morphology characterized by cellular enlargement (mostly due
to increased biomass but failure to divide) while quiescent cells have a more heterogeneous cell
morphology. The major differences between both phenotypes are summarized in Table 1.
Because of all these phenotypic differences between the two phenotypes, limiting the main
difference in the pattern of growth arrest is inaccurate. In fact, this approach has hindered novel
propositions trying to investigate the instability of the senescent growth arrest in certain
experimental system, simply because a less durable arrest must be quiescent. This circular
argument usually ignores careful phenotypic evaluation of both phenotypes, where in certain cases,
a senescence-triggering stimulus results in a reversible senescent arrest in the absence of
quiescence-related features.
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Causes

Quiescence

Senescence

Mitogenic deprivation,

Telomere dysfunction,

contact inhibition, loss of

oncogene overexpression,

adhesion

exposure to DNA damaging
agents

Growth arrest

Transient

Durable

Phase of cell cycle arrest

G0

G1 or G2

Associated CDKIs

p27Kip1, p21Cip1

P16INK4a, p21Cip1, p27Kip1,
P15INK5b, Rb, p53

Response to mitogenic

Responsive

Irrelevant

Protein synthesis

Decreased

Increased

Secretory Phenotype

No

Yes

Enhanced lysosomal

No

Yes

stimuli

biogenesis

Table 1. Comparison between senescence and quiescence. Both senescence and quiescence describe patterns
of cell cycle arrest. However, each phenotype is characterized by different hallmarks. Fundamentally, the
senescent growth arrest is more stable, while the quiescent growth arrest is often resolved once the triggering
stress has resolved. Senescence has been classically described a response to telomeric attrition, amongst other
causes, that all together result in the activation of the DDR, while quiescence is more associated with nutritional
and growth factors scarcity. The DNA content of quiescent cells is that of G1 (2n) while senescent cells can have
a variable DNA content (2n, 4n or more). The CDKI involved in regulating both phenotypes are similar except
for p16INK4a which is more characteristic for senescence. Senescent cells are metabolically active and synthesize
a plethora of secretory proteins while quiescent cells downregulate ribosomal translation. Alteration in the
lysosomal biocontent in senescent cells is reflected by upregulation of SA-β-gal enzyme, something that is not
detected in quiescent cells.

32

1.4. Experimental identification of senescence
Since the senescence phenotype displays a high degree of complexity, differences amongst varying
cell lines and the lack of a single unique, universal marker, experimental identification of
senescence, both in vitro and in vivo can be tricky. Therefore, the use of a single marker to firmly
detect senescence induction in an experimental system is insufficient. In that, a comprehensive
assessment of multiple features of the phenotype is highly encouraged (177). Furthermore, the lack
of one or more features of senescence does not necessarily negate the existence of senescent cells
in culture or in viable tissues. For example, as mentioned above, senescent cells exhibit remarkable
enlargement in cellular size in vitro, a feature that can easily be detected by bright field
microscopy; however, such changes are very difficult to detect in animal tissues or human samples.

1.2.4.1 Detection of DDR activation.
A comprehensive confirmation of senescence generally requires assaying for components of the
DDR, the initial triggering event in senescence induction. This includes the detection of
phosphorylated ATM or p53 and the resulting phosphorylation of H2AX (γH2AX); the latter is an
established marker of the formation of DNA double stranded breaks (55). Another commonly used
marker of the DDR that is often measured as an indication of senescence-associated DNA damage
is the formation of p53 binding protein 1 (53BP1) foci (55). In fact, for a more rigorous assessment
of the formation of DNA damage foci and activation of the DDR, colocalization of γH2AX and
53BP1 foci as detected by high resolution fluorescent microscopy is considered ideal (178). This
relocalization of 53BP1 is indicative of the recruitment and initiation of DNA repair processes
(179). It is important to note here that the detection of these markers is likely to be successful early
on following the exposure of a proliferating cell to a senescence-inducing stimulus e.g., the
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exposure of a tumor cell to ionizing radiation, a time period where many other senescence features
are not yet established.

1.2.4.2 Identification of cell cycle arrest
The most typically assayed features of senescence are components of growth arrest. As mentioned
above, senescent cells contain variable DNA contents depending on which phase of the cell cycle
the blockade was enforced. Thus, a traditional analysis of the DNA content (cell cycle analysis)
using a nucleic acid binding dye, such as propidium iodide, provides a useful mean to detect and
characterize the phase of the growth arrest (180). The majority of tumor cells exposed to
conventional cancer chemotherapy are arrested in the G2-M phase as they undergo senescence
(181). Again, this could vary depending on the DNA damaging agent used. The proliferation
potential of cells can be studied by a colony-forming assay which measures the capacity of cells
to form a viable cluster of cells; an impaired ability of stably arrested senescent cells, as well as
the detection of DNA synthesis proliferation markers such as using the BrdU incorporation assay
(182). BrdU, which is a synthetic analogue of thymidine, is actively incorporated into newly
synthesized DNA once available in the surrounding of a proliferating cell. i.e., in the culture
medium. Measurement of BrdU incorporation provides a useful tool to assess the proliferative
status of cells, and thereby the lack of proliferation that accompanies the senescent cell cycle arrest
(182). However, lack of such proliferative markers can also be evident in quiescent cells and the
interpretation of such observations should be done carefully, again, and in combination with other
senescence markers. Lastly, the detection of induced or activated CDKI is another commonly used
means to assay for senescence. p16INK4a is the classical CDKI that is very often measured in aging
fibroblasts and appears to show uniqueness to the senescent phenotype (183). p21Cip1 induction is
also frequently measured as part of the DDR as well as a CDKI that plays an important role in
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senescence (51). However, p21Cip1 is less specific to senescence than p16INK4a since it could be
induced of cases of non-senescent cell cycle arrest and quiescence (172). Because many tumor
cells suppress p16INK4a, the detection of p21Cip1 is very important to identify senescence in these
cells.

1.2.4.3 Measuring the upregulation of SA-β-gal
The most widely used marker for senescence is SA-β-gal (184). SA-β-gal activity can be detected
at pH=6 of the staining solution (relatively high pH) containing a chromogenic substrate of the
enzyme that is converted to blue, insoluble product after being metabolized by SA-β-gal (184).
The resulting staining can be readily detected by light microscopy. Recently, a plethora of
fluorogenic substrates of SA-β-gal have been developed which allow for more robust analysis of
senescent cells, including fluorescent microscopic identification of senescent cells, flow cytometry
based quantification of SA-β-gal positive cells and flow cytometry based purification of senescent
cells (185). More importantly, the plasma membrane is highly permeable to these fluorogenic
substrates, which allows for the detection of live senescent cells in culture in comparison with the
classical histochemical staining that requires fixing the cells/tissues. SA-β-gal is positive in almost
all senescent cells and has been the gold standard assay for senescence as its upregulation reflects
enhanced lysosomal biogenesis as discussed earlier (78). Despite its wide use and reliability, using
SA-β-gal as an absolute marker of senescence has some limitations. For example, SA-β-gal is not
entirely specific, and cells that are handled badly in culture or grown at high confluence can
express some SA-β-gal activity without being actually senescent. Also, SA-β-gal is not always
detectable in pre-malignant lesion (e.g., melanocytic naevi) harboring abundant oncogene-induced
senescent cells (186). Finally, despite the established changes mitochondrial function and cell
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membrane structure that occur during senescence, these are not frequently assayed for in this
context (32). However, recent reports identified senescence associated surface markers that could
serve useful in the future (187).

1.2.4.4 Detection of SAHF
The epigenetic modulations and structural changes in chromatin can also be assayed for in
senescent cells. These can be simply monitored using fluorescent microscopy and nucleic acid
stains which reveal bright, condensed foci of DNA (135). This could be improved by measuring
the formation of specific histone modifications that are part of the SAHF such as H3K9Me3 and
HP1 modifications (177,188). However, these markers are not absolutely specific to senescence
and in certain occasions can be restricted to certain forms of senescence as well (172). Specifically,
they have been closely associated with oncogene-induced senescence (135). On the other hand,
downregulation of Lamin B1 has been now established as a valid marker of senescence (132).
Lamin B1 levels decrease rapidly within the first few days of exposure to cellular stress, a decline
that is not often observed in quiescent cells (132).

1.2.4.5 Measuring the upregulation of SASP
The SASP is the primary functional marker of senescence and reflects the dramatic changes in
gene and protein expression that occur as part of senescence. The SASP comprises different
families of both soluble and insoluble proteins, such as cytokines, chemokines, growth factors,
structural matrix proteins and proteases (85). Despite the variability in the SASP profile amongst
different cell types, some SASP factors appear to be more consistently associated with senescence.
IL-6 is a proinflammatory cytokine that has been frequently observed as part of the SASP induced
in both human and mouse cells and in response to different senescence-inducing stimuli
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(85,93,189). Both α and β subtypes of IL-1 are also common components of the SASP of several
types of senescent cells (190,191). IL-8 is a soluble chemokine that is often detected as part of the
SASP along with IL-1 and IL-6 where they all create a regulated signaling loop (192). Several
other chemokines of both the CCL and CXCL families are often expressed as part of the SASP
(193). In addition, senescent cells secrete soluble growth factors such as multiple isoforms of
IGFBP family (194). Interestingly, senescent cells can robustly secrete different matric
metalloprotease (MMPs) that actively modulate the surrounding connective tissue (195). In further
contribution to extracellular matrix (ECM) modulation, senescent cells also secrete structural,
insoluble large proteins such as fibronectin (196).
The measurement of the upregulation of multiple SASP components that represent different
functional groups is highly recommended. For example, a routine analysis of the SASP would
include a cytokine (e.g., IL-1β), a chemokine (CCL2), a metalloprotease (MMP-3) and a soluble
growth factor (TGFβ). This comprehensive analysis is often coupled with measurement of a CDKI
expression level (e.g., p21Cip1) as confirmation of senescence induction. Fortunately, measurement
of gene expression levels of these different molecules at the message level (mRNA) is widely
accepted as those levels consistently reflect the change in their protein levels (93). Thus,
quantitative real-time polymerase chain reaction (qRT-PCT) is routinely and reliably used to
identify the alteration in gene expression in senescent cells. However, in certain occasions, the
measurement of the secreted protein levels of certain molecules such as IL-6 using enzyme-linked
immunosorbent assay (ELISA) can be adventitious. Overall, including an analysis of SASP
expression has become an important component of any senescence identification testing panel.
In conclusion, senescence is a complex phenotype that encompasses a spectrum of characteristic
features, each one of them lacks universality or specificity to senescence. Accordingly,
37

experimental detection of senescence should always consider the measurement of multiple
senescence markers for a more careful assessment. In addition, time after which a senescentinducing stimulus is introduced intro a biological system should be always considered as different
features of the senescent phenotype have variable temporal profiles. Lastly, the heterogeneity of
the senescence presents as an additional complexity as the gene expression alteration can vary
among different senescent cells that belong to the same biological environment (197). In this work,
we utilize a combination of these markers to identify the induction of senescence in our
experimental system.
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Chapter Two: Reversibility of Therapy-Induced
Senescence.
2.1. Introduction
As discussed in detail previously, Leonard Hayflick published his seminal work on the replicative
lifespan of dividing cells, which has subsequently been established in the scientific literature as
the Hayflick Limit (7). In summary, his finding that normal cells had a finite capacity to divide
was subsequently shown to be a consequence of telomere shortening that acted as a counting
mechanism to determine the number of divisions the cell had completed; when the telomere
reached a critically short length, division was terminated and the cells entered a state of terminal
senescence (198). Initially, Hayflick’s findings were not readily accepted by the scientific
community since they contradicted the paradigm of Nobel Laureate Alexis Carrel that established
the replicative immortality of cells dividing in culture (4,199).
The concept of terminal senescence has largely withstood the test of time since senescence is
virtually always defined as an irreversible form of growth arrest (28). Unfortunately, adherence to
this paradigm may have interfered with the acceptance of findings in the literature that suggest that
senescence may be reversible (91,200). In this chapter, we will describe this previous literature
that provides observations suggestive of the reversibility of senescence, focusing exclusively on
the senescence induced by cancer chemotherapeutic drugs and radiation, which is largely unrelated
to telomere shortening (24). It is very important to note here that this proposition does not indicate
by any means that senescent cells revert back to the non-senescent state completely in a similar
fashion to a reversible chemical reaction; instead, the reversibility of senescence describes the
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ability of cells to overcome the stable growth arrest and resume proliferation. The term
“senescence” will always describe stable forms of growth arrest in most cases, especially when
aging fibroblasts undergo replicative exhaustion, i.e., classical senescence. Accordingly, escaping
senescence happens only in limited cases, such as during transformation when oncogene-induced
senescence is bypassed by the accumulation of oncogenic mutations, or as we are proposing here,
following exposure of genetically unstable tumor cells to senescence-inducing anticancer therapy.
There are several reasons why we think that experimental testing of the spontaneous escape of
tumor cells from senescence is important to establish. While the intent of radiation and
chemotherapy is to kill the malignant cell, generally through the promotion of apoptosis or other
cell death pathways, it must be recognized that not all tumor cells will of necessity undergo cell
death upon being subject to therapeutic strategies. Recognizing the heterogeneity of any tumor
population, it is not difficult to imagine that there are some cells that are likely to evade the
cytotoxic effects of treatment and undergo growth arrest as an alternative response. One type of
growth arrest will be that of quiescence from which the cells can ultimately recover (201). In the
case of irradiation or DNA damaging drugs, this is generally thought to occur when the DNA is
repaired. However, in this context, a generally circular argument is often advanced that when
tumor cells are shown to re-emerge from the growth arrested state, then by definition the growth
arrest must have reflected quiescence rather than senescence, since senescence is virtually always
considered to be irreversible (202). It is, however, now well-established in cell culture, in tumor
bearing animal models, as well as in clinical samples, that senescence is not infrequently a primary
response to therapy (58,181,203,204), and that senescence could possibly be reversible.
The consequences of Therapy-Induced Senescence (TIS) are not well understood. In terms of cell
autonomous effects, a fundamental question is whether senescence is beneficial or undesirable
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with regards to therapeutic outcomes. If TIS is truly irreversible, then this would be partially
considered a desirable if not ideal outcome since the tumors driven into this state should never reemerge (166). Moreover, it is further possible that, as suggested by some previous work, that
senescent cells may be recognized and eliminated by the immune system, which would convert
growth arrest into cell death (205). However, if TIS has a potential to be reversible, this could have
serious clinical ramifications. That is, the senescence response may provide an avenue whereby
tumors escape from drug and radiation killing only to remain dormant at either the primary tumor
site or an occult niche after having metastasized. In addition, senescent tumor cells may represent
a component of minimal residual disease that is often associated primarily with circulating tumor
cells. This senescent cell population, which is generally considered to be resistant to apoptosis (21)
could ultimately contribute to disease recurrence. Lastly, since, virtually by definition, dormant
tumor cells in patients are occult and difficult to be identified (being few in number and
inaccessible) (206), and mostly revealed in autopsies (207), one can only extrapolate from studies
in cell culture and ultimately in animal models whether, in fact, senescent cells can give rise to
resurgent tumors.

2.2 Evidence for the reversibility of Therapy-Induced Senescence (TIS).
As indicated above, the debate about the reversibility of senescence has suffered from the circular
argument that if cells are observed to recover from a state of senescence, then the recovering cells
could not have originated from the senescent population. Consequently, researchers have often
resorted to terminology such as such as “senescence-like” and “pseudo-senescence” in reference
to cells with characteristics of senescence that have escaped from prolonged growth arrest (208–
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210). While this terminology is acceptable, it tends to minimize the validity of the observations
that cells exhibiting certain features of senescence can overcome the durable growth arrest.
Early studies from our group have demonstrated that clinically relevant concentrations of
adriamycin induce p53-dependent cellular senescence in MCF7 breast tumor cells (26). In this
study, a small population of MCF7 cells recovered from acute adriamycin exposure and a
senescence-resistant colony was isolated. This colony, which recovered from the senescent
population, stopped responding to subsequent exposures to doxorubicin by undergoing senescence
(26). In comparison with parental cells exposed to doxorubicin, the senescence-resistant colony
expressed higher levels of proliferative cell cycle regulators, such as cyclin B1 and E2, PCNA and
cdc2, following adriamycin treatment. In fact, continuous expression of cdc2 is more likely to
account for the ability of these cells to evade senescence. Furthermore, this resistance was not due
to decreased intracellular accumulation of adriamycin or because of an attenuated DDR since the
resistant colony continued to respond to adriamycin by p53 and p21Cip1 induction (26) . These
initial experiments suggested that certain tumor cells with altered genetic background can possibly
evade senescence or at least acquire senescence-resistant traits.
A number of reports by the Wu group at the University of Washington have largely supported the
ability of tumor cells to evade therapy-induced senescence (89,209,211). In one study, H1299 nonsmall cell lung cancer (NSCLC) cells, which are null in p53 and deficient in p16INK4a, were induced
into senescence by camptothecin and other chemotherapeutic agents such as etoposide and
cisplatin (89). Since the choice of a cell line lacking pivotal senescence regulatory proteins could
be a deficiency, the authors indicated that genes encoding for p53 and p16INK4a are frequently
mutated in clinical cancer and this model is representative for clinical cancer. In this case,
senescence induction in H1299 cells was confirmed based on large, flat morphology, increased
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granularity, retention of PKH2 (a cell membrane staining dye ـــretention is suggestive of lack of
cell division) and finally, upregulated SA-β-gal expression. Interestingly, a small population of
senescent cells were subsequently observed to regain proliferative capacity resulting in the
formation of colonies 3 – 4 weeks after removal of drug; the frequency of escape was 1 in 106 cells
suggesting that (i) the stability of the senescent growth arrest is the more predominant phenotype
in agreement with the established conception of senescence and that (ii) escape of tumor cells from
senescence is a rare event (89). In disagreement with the Elmore et al. study, where the senescenceresistant cells developed cross-resistance to multiple senescence-inducing drugs (26), the
senescence-escaped cell colonies were found to have similar sensitivity to camptothecin as the
parental H1299 cells, indicating that these cells did not arise from a senescence-resistant H1299
cell population (89). However, this escape from senescence was also associated with sustained
expression of cdc2, suggesting that it plays an important role in evasion from senescence.
Interestingly, cdc2 levels were elevated in clinical tumor samples from patients who received
adjuvant chemotherapy and developed abundant tumoral senescence as marked by SA-β-gal
staining (89).
Polyploidy, which reflects cells containing more than three times the number of haploid
chromosomes, is a common feature of senescent cells. In a follow up study by the Wu group, Wang
et al. demonstrated that many camptothecin-induced senescent H1299 cells are polyploid (209).
Interestingly, 40% of these polyploid senescent tumor cells were able to uptake EdU several days
after senescence induction, suggesting that they could still undergo DNA replication. Using live
cell imaging and H2B-RFP labeling (that allowed fluorescence visualization of the nucleus), Wang
et al. also showed polyploid senescent cells escaping from senescence. To confirm the live imaging
study, camptothecin-induced senescent cells were sorted based on size and the large, polyploid
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cells plated. Colonies were observed 7 – 10 days after seeding (209). Again, escape from
senescence was found to be related to overexpression of Cdc2 in agreement with the previous
observations (26,66). It was further demonstrated that therapy-induced cell senescence in patients
with locally advanced NSCLC was associated with poor prognosis. Wang et al. found that survivin,
which is downstream of Cdc2, is upregulated and plays a role in escape from senescence, as well
as the subsequent viability of the escaped cells (211).
Polyploidy is likely to be a requirement for recovery from senescence since only multinucleated
cells will have the capacity to generate replicating daughter cells. Studies by Mosienak et al
identified polyploidy in HCT116 cells where senescence was again induced by doxorubicin (212).
When polyploidy was abrogated, the cells were unable to escape from senescence. Moreover,
MCF-7 cells that were shown to undergo senescence but not polyploidy upon doxorubicin
treatment were unable to escape from senescence (212).
Was et al. also established the reversibility of senescence in their study where HCT116 cells were
treated with 3 cycles of 24 h doxorubicin and 72 h drug-free treatment (213). Senescence was
evident after 13 d based on flattened cell morphology, cell enlargement and increased granularity,
SA-β-gal expression, as well as secretion of VEGF and IL8, components of the SASP (213). Here,
also, senescent cells were shown to exhibit polyploidy. A 6-fold increase in cell number 2 weeks
following removal of doxorubicin indicated an escape from senescence. Time-lapse imaging
revealed proliferating cells in the polyploid, senescent cell population. Consistent with reports in
literature of senescent cells exhibiting stem cell features (214,215), CD24+ (about 1.5% of cells)
and NANOG exhibiting stem cell-like cells were also observed in the treated cell population (213).
Doin et al. demonstrated that cisplatin treatment both in vivo and in vitro results in an initial
cessation of cell division and proliferation that is eventually succeeded by cells recovering from
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growth arrest (216). Cisplatin treatment of PROb cells in vitro resulted in significant cell growth
arrest but continued DNA replication. Again, live cell imaging using the fluorescent H2B-GFP
showed the emergence of largely senescent giant polyploid cells which eventually disappeared due
to depolyploidization and resumption of cell proliferation through atypical mitotic division
(216).The observation of colonies of cells arising from the senescent cells lends further credence
to the reversibility of senescence. When cisplatin was administered to PROb colon cancer tumor
bearing BD-IX rats, there was significant tumor shrinkage characterized by giant polyploid cells,
most of which stained positive for SA-β-gal (216). Tumors were observed to resume growth 1
month after drug administration during which time SA-β-gal was significantly absent, indicating
that cisplatin treatment delayed but did not stop tumor growth (216).
The development of polyploidy followed by depolyploidization and atypical mitotic division was
also demonstrated by Rohnalter et al. (217). In this study, carboplatin-treated SKOV3 ovarian
cancer cells proceed through a series of stages that result in a chemoresistant phenotype (217). The
multi-staged process included mitotic catastrophe, polyploidization, cell cycle arrest and
senescence followed by the acquisition of stemness, increased cell divisions, depolyploidization,
and eventually chemoresistance at 21 weeks following treatment. One of the most distinct features
of this multi-staged process was the presence of giant cells that exhibit polyploidy. The process
was accompanied by an initial increase in p21Cip1 that peaks at day 8 and begins to decrease as
cell division increases and giant cell numbers decrease (217). The emergence of a subpopulation
of cells that are capable of cell division and are chemoresistant is suggestive of the reversibility of
carboplatin-induced senescence and the possible contribution of senescence to tumor resurgence
or treatment relapse.
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Sabisz and Sklandanowski studied senescence and escape of a subpopulation of A549 NSCLC
cells (208). Here, senescence was induced with the topoisomerase II inhibitor etoposide. Similar
to the Wang et al. study, about 20% of the senescent cells were found to exhibit polyploidy over
the course of the study. Levels of p53 and p21Cip1 were also found to increase progressively while
Cdc2 and cyclin B1 increased after 1-2 d and decreased beyond detection at day 5 (208). Following
drug treatment for 5 days, cells were incubated in drug-free media and between 1 and 3% of the
cell population was observed to regain proliferative capacity at 10 days post-treatment. Sabisz and
Sklandanowski determined that about 1.1% of the treated cells expressed markers of cancer cell
stemness (CD34 and CD117); given that this number was very similar to the senescence-escaped
cell population, it was suggested that the two cell fractions could be the same, and that cells
escaping senescence acquire stem cell-like characteristics (208). For example, a study by Achutan
et al involving multiple breast cancer cell lines (MCF-7, MDA MB231, and T47D) and primary
tumors also revealed that cells that escaped from doxorubicin-induced senescence could be from
the cancer stem cell population (210). The small population of cells that escaped senescence were
found to exhibit stem cell characteristics and to express increased levels of the stem cell marker
CD133 (210).
The cornerstone of these studies is a recent report by Clemens Schmitt group. These studies were
based on the emerging association between senescence regulatory pathways and stem cell
functions or “stemness” (218). In agreement with previous observations, Milanovic et al
demonstrated that a single exposure of Eμ-Myc  ـــBcl2-overexpressing lymphoma cells to
adriamycin (0.05 μg ml−1) resulted in a robust senescence induction (marked by over 80% SA-βgal staining) and an accompanying increased expression of stem cell related genes as well as
elevated activity of aldehyde dehydrogenase (ALDH) and ATP-binding cassette (ABC), both
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associated with stem cell function (90). Importantly, enhanced stemness was not detected in cells
exposed to the same concentration of adriamycin but that failed to undergo senescence (due to the
absence of Suv39h1 enzyme which is responsible for the senescence-associated epigenetic
signature H3K9Me3) (90). These studies established that enhanced stemness is a feature of
chemotherapy-induced senescence in tumor cells. Using an inducible expression model for p53
and Suv39h1, the authors were able to deactivate these pro-senescence proteins and facilitate
resumption of S phase activity after adriamycin-induced senescence (marked by EdU staining and
gradual decline in SA-β-gal activity). Although the reversal of senescence was not fully
spontaneous, the authors concluded that p53 inactivation is a common aberration in tumor cells
and the possibility of evading the permanent cell cycle arrest is strong. In fact, they stated that
“senescence is, in principle, a reversible condition, which becomes evident when essential
senescence maintenance genes are no longer expressed” (90). Moreover, the cells that escaped
senescence were able to undergo senescence again in response to adriamycin, indicating that no
senescence-resistance phenotypes had developed. An additional interesting finding of this work is
that cells that escaped TIS and acquired stem cell properties were more aggressive, forming rapidly
growing colonies in vitro and more malignant tumors when implanted in vivo (interestingly, in
immunocompetent mice). In summary, TIS results in extensive pro-stemness genetic reprograming
that facilitates escape from the permanent growth arrest and possibly represents a component of
relapsed cancer. Another important conclusion from this work is that tumor cells that escaped
senescence are more malignant.
In support of the Milanovic et al study, Yang et al also demonstrated that A549 NSCLC cells
exposed to adriamycin (100 nM) for 7 days can resume proliferation after 21 days of drug-free
culture (219). However, unlike the studies in the lymphoma cells where p53 inactivation was
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necessary for escaping senescence, Yang et al. demonstrated a spontaneous reversion of A549
senescent cells into the proliferative state (219). Lastly, the cells that escaped senescence exhibited
more invasive and migratory properties.
These findings of reversible senescence are not limited to chemotherapeutic drugs. Senescence
induced by ionizing radiation has also been found to be reversible in some studies(164,220,221).
Chitikova et al. described the reversal of radiation-induced senescence in apoptosis-resistant
E1A+E1B cells (221). Cells were shown to arrest in the G2-M phase of the cell cycle while DNA
replication significantly decreased 24 h following ionizing radiation treatment (221). Resumption
of DNA replication occurred 48 h after treatment with an attendant polyploid cell accumulation.
Polyploid cells were enlarged, flattened and expressed SA-β-gal, consistent with senescence. Cell
proliferation following the induction of senescence was observed 7 d post-irradiation. Increased
expression of stem cell markers NANOG and OCT3/4 was also observed with the proliferative
recovery (221).
In our own studies with MCF-7 breast tumor cells, widespread senescence was observed as
demonstrated by SA-β-galactosidase expression with 10 Gy ionizing radiation (164). Continuous
culture of the senescent cells revealed proliferative recovery of the cells. We have also
demonstrated in our work with DNA repair proficient and deficient HCT116 cells, that radiationinduced senescence associated cell growth arrest was ultimately reversible with or without Poly
(ADP-ribose) polymerase (PARP) inhibition (220).
In summary, multiple observations in the literature point out with experimental evidence the
potential of tumor cells to re-enter the cell cycle after senescence. However, these conclusions
relating to the re-emergence of tumor cells from senescence have generally been based on studies
in mass culture, where the origin of the replicating cells cannot be unequivocally attributed to the
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senescent population. Furthermore, the interpretations of most of these observations were kept
fairly conservative, largely to avoid generating provocative postulates that might appear to
undermine the prevailing paradigm.

2.3 Dissertation Objectives
The main objective of this dissertation is to directly address the hypothesis that a subpopulation of
tumor cells induced into senescence by genotoxic conventional cancer therapy can re-acquire
proliferative capacity after a period of cellular dormancy to form viable colonies and growing
tumors in vivo. The observational evidence should unequivocally demonstrate that any restoration
of growth from a presumably senescent population should originate from a senescent cell and not
from non-senescent cells that were either resistant to the anticancer agent or have been temporarily
arrested without displaying senescence hallmarks. The specific aims for this work are:
Specific aim 1: To induce a robust senescent phenotype in tumor cells based on the identification
of multiple senescence hallmarks.
For this aim, senescence will be induced in models of lung and colorectal cancer. Lung cancer and
colorectal cancer represent the second and third most common cancers that affect both sexes; both
types of cancer account for the majority of cancer-related deaths, with lung cancer being the most
common cause of cancer death in the United States (222). Lung cancer is histopathologically
divided into non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC
represent the majority of lung cancer cases (~85%) and consequently, the majority of cancerrelated deaths. Accordingly, we will be focusing on NSCLC and using primarily the H460 NSCLC
(large cell carcinoma) and A549 NSCLC cell (adenocarcinoma) cell lines. Both cell lines are
frequently used as models to study molecular processes involved with lung cancer. Lung cancer is
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initially a silent disease which represents a diagnostic problem. Therefore, many cases of NSCLC
are not diagnosed until later in the disease where most patients present with unresectable tumor.
Consequently, the standard of care for the treatment of late-stage lung cancer is chemotherapy.
In patients with overexpression of the epidermal growth factor receptor (EGFR), which involves
approximately 10-15% of the population, a number of new drug therapies have demonstrated
various degrees of success (223). In this context, a number of other targeted therapies are under
investigation with the goal of developing more individualized approaches based on both molecular
and histological characterization (224,225). Of these novel therapies, drugs that target the
Anaplastic Lymphoma Kinase (ALK) have shown significant reductions in tumor volume or
maintenance of a stable disease state in a subset of lung cancer patients with rearrangements in the
ALK gene; such fusion lesions render cells dependent on ALK signaling and susceptible to the
actions of tyrosine kinase inhibitors (226). In almost all cases, ALK genetic rearrangements have
been linked to mutations in other oncogenes such as EGFR and K-Ras and, interestingly, in
patients who are mostly young and with low or no history of tobacco consumption (226,227). In
addition, several immunotherapies have also been developed as second-line treatment for
advanced cases that fail to respond to platinum therapy. Nivolumab, an anti PD-1 receptor
monoclonal antibody, was approved by the FDA in 2014 and has shown acceptable clinical
efficacy in patients with terminal squamous cell carcinoma and overall survival superiority over
other checkpoint inhibitors (228,229). There is no evidence thus far that check point inhibition
therapy will induce senescence in tumor cells, or that EGFR inhibitors can induce senescence in
lung cancer cell lines in vitro (167).
Despite these considerable advancements in targeted therapy of lung cancer, the primary
therapeutic strategy for most patients with advanced disease remains radiation therapy in
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combination with cytotoxic chemotherapy, i.e. chemoradiation. The primary drugs currently used
in chemoradiation are cisplatin and carboplatin (platinum-based, DNA cross-linking), paclitaxel
and docetaxel (microtubule poisons) and etoposide (topoisomerase II inhibitor) (230). Microtubule
poisons show higher efficacy against lung cancer; however, paclitaxel for example is a weak
senescence inducer, mostly because it does not robustly activate the DDR and exerts its effects
through disruption of mitosis (181). Cisplatin on the other hand has been shown to robustly induce
senescence in lung cancer cell lines, especially at subtoxic concentrations (231). Topoisomerase
poisons have been used as potent senescence inducers, not only in tumor cells, but in a variety of
other cell lines (58). While adriamycin is the most established senescence-inducing agent, it is
infrequently used as primary treatment of lung cancer, and thus, we will be focusing on etoposide,
another topoisomerase II inhibitor, that can also robustly induce senescence in lung tumor cells
(232). It is important to note here that the experimental use of such drugs will be completely for
the purpose of inducing senescence in these lung cancer models rather than stimulating their
clinical use, especially in cell culture studies. Lastly, senescence identification in the lung cancer
cells will be evaluated based on available senescence hallmarks (discussed in chapter 1) relying
heavily on SA-β-gal assay as it is the classical, most accepted approach to evaluate senescence
(184).
Specific aim 2: To directly test the possibility of escaping Therapy-Induced Senescence in vitro
using both lung cancer and colon cancer cell lines.
After establishing a senescent state in tumor cells, the tumor cells will be monitored over time for
signs of proliferation. These observations will be recorded in mass, heterogeneous population of
cells exposed to etoposide for senescence induction as well as in a senescence-homogenous
population where senescent cells will be isolated using flow cytometry based on senescence
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markers. Our approach will utilize flow cytometry based purification of highly senescent cells in
combination with single cell analysis and direct cell lineage monitoring to ensure that any evidence
of proliferation or escape from the cell cycle arrest is originating from a previously senescent cell.
Specific aim 3: To test if senescent tumor cells can form viable tumors in vivo.
An important aim of this work is to establish if a tumor cell recovering from senescence can form
a viable tumor upon introduction into mouse. The impact of the immune system on the surveillance
of senescent cells and their potential escape from senescence is profoundly important. It is now
appreciated that select cytotoxic chemotherapies and radiation can enhance tumor cell
immunogenicity by promoting immunogenic cell death (ICD) (233). A requirement of ICD is
therapy induced autophagy which, when left unresolved, results in apoptosis. Under conditions
where TIS results in an immune suppressive SASP, the benefits of ICD can be lost. This could
happen frequently as therapy treated tumors will likely contain a mixture of cells undergoing
immune stimulating ICD and immune suppressive TIS (234).
Generally, in those circumstances where therapy induces ICD, the immune response can eliminate
the tumor cells (235). However, TIS is less deterministic as it can promote both pro- and antitumor immune activities (236). Central to the variability of the immune response to TIS is the
SASP (85). The SASP is capable of attracting and further differentiating a variety of pro- or antitumor immune cells in the tumor microenvironment including natural killer (NK) cells,
neutrophils, monocytes/macrophages, and T cells (237). How immune cells respond to the SASP
depends on which chemokines are secreted, which in turn depends on how the tumor cell responds
to chemotherapy (238). Depending on this response, SASP can lead to the elimination or the
protection of tumors cells, where the latter could represent a key element for maintaining tumor
cell dormancy and its potential recurrence (239). However, the consequences of TIS to the
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antitumor immune response are less well characterized, largely due to difficulties in generating a
pure population of senescent cells to study, in contrast to OIS, which has been studied in multiple
contexts and has been reviewed extensively (240).
However, since tumor cell lines that we will be utilizing in our studies will be primarily of human
origin, in vivo approaches will be restricted to immunodeficient animal models. The impact of the
immune system on TIS is not a focus of this project, but the ability of senescent cells to form
tumors following recovery will be tested experimentally.
Specific aim 4: To test possible approaches to selectively eliminate senescent tumor cells in effort
to enhance the efficacy of cancer therapy and possibly interfere with recovery from senescence.
Recent efforts have shown that the selective removal of senescent cells from progeroid animals
delays the onset of several aging phenotypes and ameliorates already established pathologies
(241). This approach, which was based on a genetic model of a p16INK4a suicide gene has been
extended to identifying novel molecules that can eliminate senescent cells in a similar fashion;
such drugs are referred to as senolytic agents (242,243). The term “senolytic” describes the ability
of these drugs to selectively eliminate senescent cells. These promising efforts have been largely
restricted to progeroid models (with little focus on senescent tumor cells) or to merely
experimental therapies. Our goal here is to use these novel compounds, primarily the Bcl-2
inhibitor, ABT263 (Navitoclax), to eliminate senescent tumor cells that have been exposed to
chemotherapy. Furthermore, we will be testing whether the use of ABT263 to eliminate senescent
cells will attenuate the ability of tumor cells to recover from senescence.
Specific aim 5: To investigated the impact of autophagy inhibition with the ability of cells to
recover from Therapy-Induced Senescence.
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Autophagy has historically been considered as a defensive mechanism that is observed under
conditions of cellular stress, responsible for metabolic compensation and organelle turnover (244).
However, multiple other functions of autophagy have been characterized in different cancer cell
lines, where it can play an anti-survival role or act as a cellular mechanism mediating sensitization
to therapy (245).
Many of the chemotherapeutic agents that are commonly utilized in the treatment of non-small
cell lung cancer and induce cellular senescence have been also shown to induce autophagy in
parallel (140). Since that the metabolic stability of senescent cells is required for their survival, we
will be testing the effect of autophagy modulation on senescence maintenance and, more
importantly, whether recovery from senescence is dependent on autophagic metabolic regulation.

2.4 Summary
It is not difficult to imagine that the majority of tumor cells undergo cell death and recruit a robust
immune response to cytotoxic therapies, leaving small and undetectable subpopulations of cells
hiding in a dormant state. While having a pivotal impact on the natural history of cancers, we have
a limited understanding of tumor dormancy. We know that it represents a phase where tumor cells
persist in an occult state as part of the post-treatment residual disease (246). Furthermore, the
mechanisms by which tumor cells transition into the dormant state, at primary or distant sites, and
then restore growth capacity are still speculative (246). In addition, the stimuli that promote escape
of dormant tumor cells remain to be identified. There is a general agreement that dormant tumor
cells are in a quiescent state, simply because quiescence is, by definition, reversible (202).
Ironically, all of the postulated mechanisms that would theoretically facilitate the recovery of
dormant cells can be closely associated with senescence (202,247). For example, dynamic
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alterations of the microenvironment and restoration of blood supply, critical events contributing to
the capacity of dormant tumor cells to recover (248), are heavily influenced by SASP factors such
as matrix metalloproteinases and angiogenic promoters such as VEGF. Moreover, as discussed
earlier, senescent cells not only interact with, but also modulate the immune system, thus possibly
contributing to evasion of immunosurveillance. In addition, senescent cells are resistant to
apoptosis, metabolically active and can persist in vivo for prolonged periods.
A primary purpose of this work has been to propose the argument for senescence as model of
tumor dormancy, wherein a subpopulation of cancer cells that escape cell death following bouts
of cytotoxic therapy undergo senescence and persist for weeks or even months. These dormant,
senescent cells secrete an array of soluble and non-soluble molecules that gradually alter the
surrounding tissue and slowly promote angiogenesis (249). Eventually, a few senescent cells that
manage to undergo proliferative recovery and escape immunosurveillance would be competent to
take advantage of the changes in the ECM and the restored blood supply to re-initiate tumor
formation. However, this proposed model requires the experimental validation that senescent
tumor cells can actually evade the non-permanent growth arrest which is the main aim of this
work.
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Chapter Three: Recovery of tumor cells from a senescent
state induced by etoposide.
3.1 Introduction
It is often thought that tumor cells exposed to chemotherapy or radiation all experience an identical
fate; however, the response(s) are more likely to be heterogeneous (250). These can include cell
death (often through various forms of apoptosis and/or mitotic catastrophe) as well as variable
forms of growth arrest that include autophagy, quiescence and senescence (58,204,251–253). Not
all of these processes will be strictly terminal, with the consequence that some tumor cells may
survive and contribute to disease recurrence.
Cellular senescence is a well-established, highly-programmed response to various DNA damaging
antitumor modalities wherein the cells enter into a durable and prolonged growth arrest that is
generally considered to be irreversible (172,181,254). The senescent phenotype is characterized
by a spectrum of distinctive features (32). These hallmarks include activation of the DNA damage
repair response (255), enhanced lysosomal biogenesis as indicated by the upregulation of the
classical Senescence-Associated-β-galactosidase (SA-β-gal) enzyme (78), extensive alterations in
gene expression (82,83,256), and epigenetic modifications collectively referred to as SenescenceAssociated Heterochromatin Foci (SAHF) (188,257). An additional hallmark of senescence is the
Senescence-Associated Secretory Phenotype (SASP), wherein cells secrete a spectrum of
chemokines and cytokines, many of which are thought to promote tumor growth (85). Quiescence
is a more transient form of growth arrest from which cells are observed to rapidly recover,
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presumably as a consequence of effective and efficient DNA repair that allows the cells to
circumvent checkpoint-mediated arrest.
The durability of the growth arrest is a primary characteristic that distinguishes senescence from
quiescence (172). Although a permanent abrogation of tumor growth (i.e. reproductive cell death)
would be one desirable outcome of therapy short of over cell killing, there is evidence that
senescent arrest in tumor cells is not uniformly durable For instance, it has long been evident that
senescent cells retain inherent reproductive potential since transformation and immortalization
involve escape from replicative or oncogene-induced senescence (258–260). Furthermore, in a
recent report by Milanovic et al, senescence was noted to be inherently reversible only to be
stabilized into a permanent state when the senescence maintenance program (stable cell cycle
arrest, heterochromatin formation and repression of gene expression) is expressed (90). Moreover,
those tumor cells induced into senescence by chemotherapy acquired aggressive, stem-cell like
characteristics upon escape from the cell cycle blockade (90). More recently, breast tumor cells
induced into a senescent-like growth arrest by MDM2 inhibitors were shown to re-acquire
proliferative potential over time (261). In attempt to summarize these observations, a review by
our research group provides an overview of the capacity of cells to escape from the three different
forms of senescence (91). With regards to therapy-induced senescence (TIS), reports by our group
as well as other laboratories have presented additional evidence in support of the premise that
tumor cells in a state of senescence are not obligatorily in a terminally growth-arrested state
(reviewed in chapter 2). However, conclusions relating to the reversibility of senescence have
generally been based on studies in mass culture, where the origin of the replicating cells cannot be
unequivocally attributed to the senescent population.
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In this chapter, we present experimental evidence of senescence induction in tumor cells in
response to etoposide exposure. We also provide a temporal analysis of senescent tumor cells
growth and key molecular signatures following termination of treatment. Furthermore, we have
attempted to overcome one of the primary limitations of previous studies (including our own) by
utilizing two complementary experimental strategies. One was to utilize flow cytometry based
enrichment to focus the analysis on a more homogeneous populations of senescent cells, and
second was to monitor changes in single senescent cells using live microscopic imaging
techniques. Lastly, we further implant the senescent-enriched cells into NSG mice to assess their
capacity to grow out and form tumors in vivo.
We observe heterogeneous responses to the antitumor drug, etoposide, utilized at subcytotoxic
concentrations. Some cells enter and remain in a senescence-like state for the duration of the
experiment while some cells undergo cell death. However, a subpopulation of the cells expressing
hallmarks of senescence and then enriched for SA-β-gal expression appears to be capable of
overcoming a prolonged, yet, transient growth arrest to form proliferating colonies and viable
tumors in mice. It could be and is, frequently argued that these cells were not actually senescent
since they recovered proliferative capacity, but only expressed senescence markers and efforts to
identify the factors that distinguish truly irreversibly arrested senescent cells from senescent like
cells that generate proliferating progeny are under way. However, it appears possible that a
senescence-like state that is capable of giving rise to actively dividing cells could represent one
previously unrecognized form of tumor dormancy; furthermore, cells that arise from the senescentlike state and re-emerge into a proliferative state could also ultimately contributes to disease
recurrence.
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3.2 Experimental procedures
3.2.1 Cell Lines.
The H460 cell line was generously provided by Dr. Richard Moran. H460 cells were cultured in
DMEM supplemented with 10% (v/v) fetal bovine serum (SH30066.03, Thermo Scientific, MA,
USA), 100 U/ml penicillin G sodium (15140–122, Invitrogen, CA, USA), and 100 μg/ml
streptomycin sulfate (15140–122, Invitrogen, CA, USA) at 37º C and 5% CO2. The HCT116
(BTG1-RFP) cell line was developed at the lab of Dr. Igor Roninson at The University of South
Carolina. HCT116 cells were transduced with a lentiviral BTG1-RFP (dsRed) construct. Clonal
cell lines were established from the BTG1-RFP transduced cells and clones that provided the
strongest signal and induction by chemotherapy were identified. BTG1 was selected following a
microarray analysis of genes that show altered expression in tumor cells that become senescent
following exposure to chemotherapy (262). HCT116 were maintained in culture similar to H460
cells. Etoposide (VP-16-213) was obtained from Sigma-Aldrich, MO, USA (E1383).

3.2.2 Cell Viability and Clonogenic Survival.
Growth curves were determined by counting viable cells based on trypan blue exclusion at various
time points after the treatment. Cells were harvested using trypsin, stained with 0.4% trypan blue
(T8154, Sigma, MO, USA), and counted using a hemocytometer under light microscopy. The
assay is based on the fact that viable cells have intact plasma membranes and thus impermeable to
trypan blue. Colony forming assay measures the cell survival and the ability of cells to form viable
colonies. For that, H460 cells were seeded at the indicated densities and allowed to proliferate. At
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the indicated time points, cells were harvested, washed with PBS and fixed with methanol. Fixed
cells were allowed to dry overnight and then stained with crystal violet (0.01%).

3.2.3 SA-β-galactosidase Staining/Enrichment.
Histochemical SA-β-gal labeling was performed as previously described by Dimri et al. (80).
Images were generated using bright field by Olympus inverted microscope (Olympus inverted
microscope IX70, 20x objective, Q-Color3™ Olympus Camera; Olympus, Tokyo, Japan). The
C12FDG staining protocol was adopted from Debacq-Chainiaux et al. (185). At the indicated time
points, cells were harvested, washed with cold PBS, and analyzed by flow cytometry (using BD
FACSCanto II and BD FACSDiva software at the Virginia Commonwealth University Flow
Cytometry Core Facility). Similarly for fluorescent microscopy, at the indicated time points, cells
where exposed to bafilomycin A1 (100 nM) for 1 h, followed by incubation with C12FDG (33 µM)
for 2 h. Cells were washed 3 times with PBS and nuclei were stained with Hoechst 33342 for 20
minutes in complete media. Microscopy was performed with an Olympus inverted microscope.
For the enrichment assay, both H460 and HCT116 (BTG1-RFP) cells were seeded at 1-2 x 106/150
mm dish and cultured overnight before being exposed to etoposide (1 µM) for 24 h. On days 3
and 7 for H460 cells and day 3 for HCT116 (BTG1-RFP) cells, the cells were exposed to
bafilomycin A1 (100 nM) for 1 h, followed by incubation with C12FDG in complete medium for
2 h. Cells were then harvested and sorted by flow cytometry based on parameters displayed in the
supplementary data.

3.2.4 Confocal Microscopy
For γH2AX and H3K9Me3 staining, H460 cells were seeded in 4-well chamber slides (Nunc Lab
Tek, Sigma-Aldrich, MO, USA). Cells were treated with etoposide (1 µM) for 24h and within 48
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hours (or 6h for γH2AX), slides were processed for immunofluorescence. Cells were washed with
1X PBS and fixed with 1mL of ice-cold 4% paraformaldehyde (PFA) for 10 minutes. Excess PFA
was removed by washing with PBS. Cells were then treated with a permeabilizing solution (0.5%
Triton X-100 in PBS) for 10 mins and excess solution was removed by further washes with PBS.
Cells were blocked using 1X PBS 1% Casein blocker (1610783, Bio-Rad, CA, USA) for 1 hour at
room temperature. Subsequently, cells were treated with 250 µL of the appropriate primary
antibodies (mouse monoclonal anti-γH2AX at 1:2500 (05-636, mouse, rabbit, Millipore, MA,
USA) and rabbit anti-H3K9me3 (ab8898, Abcam, UK)) overnight at 4°C. After three cycles of
washing with 1 mL of PBS for 10 min (for γH2AX staining, washing was performed using 1mL
of 0.1% TritonX-100 in PBS), cells were incubated with 250µL of appropriate secondary
antibodies: goat anti-mouse AF488 at 1:5000 (A21121, Thermo Fisher Scientific, MA, USA), goat
anti-mouse CFL594 at 1:250 (sc-362277), goat anti-rabbit AF594 at 1:250 (35560, Thermo Fisher
Scientific, MA, USA), for 3 hours at room temperature. Excess antibodies were removed by
washing and cells were post-fixed using ice-cold 4% PFA for 10 min. For p21Waf1/Cip1 staining,
cells seeded in chambers were stained with anti-p21 antibody (610234, BD Biosciences, NJ, USA)
as described above. After overnight incubation, cells underwent lysosomal alkalization by
exposure to bafilomycin 1A (100 nM) for 1 h, followed by incubation with C12FDG (33 µM,
D2893, Thermo Fisher, MA, USA) in complete medium for 2 h at 37°C. The nuclei were
counterstained with Vectashield mounting medium containing 1.5 µg/mL 4ʹ-6-diamidino-2phenylindole (DAPI) (H-1200, Vector Laboratories, CA, USA). Immunofluorescence was
observed with the Zeiss LSM700 Confocal Laser Scanning Microscope equipped with a 63X, 1.4
NA oil immersion objective, located in the Virginia Commonwealth University Microscopy
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Facility. Confocal images were obtained using a 405 nm diode laser (DAPI), a 488 nm laser
(AF488) and a 555 nm laser (AF594, CFL594).

3.2.5 Live-cell Microscopy.
For live microscopy, only the high-C12FDG-positive H460 cells were reseeded and monitored for
40 h at 5 days following flow cytometry sorting. Time-lapse imaging was performed using a Zeiss
Cell Observer microscope (Carl Zeiss Microscopy, Thornwood, NY, USA), equipped with a Pecon
stage incubator (set to 37° C, 5% CO2), an Axiocam MRm camera, and a Prior motorized XY
stage (programmed to re-visit multiple selected sites in the culture dish). Phase contrast images
were collected using a 10x / 0.3 NA Plan-Neofluar objective lens at 5 min intervals over a 48 h
period. Approximately 10 fields of view were time-lapse imaged in the culture dish for each
experimental trial. Images were collected and processed using Zen software.

3.2.6 HSLCI
The HSLCI protocol has been described in detail previously (263); briefly, a wide field phase
detection camera is coupled to light emitting diode, motorized stages holding a 24 well plate, and
a piezo actuated autofocusing system. The detected phase change in the light is then used to
calculate the mass of single cells, and cell clusters. For the unsorted cell experiment, H460 cells
were plated in a 24-well optical glass-bottomed plate (P24-0-N, Cellvis, CA, USA) at 1 x104
cells/ml with a total of 1ml of medium (DMEM described above) in each well. Plated cells were
allowed to adhere overnight. Cells were then exposed etoposide (to 1 µM) and put inside the
HSLCI for imaging for 6 days at 10x or 20x, 37o C, and 5% CO2. Media was replaced after 24
hours of drug exposure and then every 48 hours after that. When using sorted cells, high-C12FDG,
low-C12FDG and untreated control cells were plated and allowed to adhere overnight, followed by
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monitoring in the HSLCI for 5 days at 10x or 20x at 37o C, and 5% CO2. Media was replaced every
48 hours. A random 10% of locations were monitored from days four to six post dosing to observe
mitosis. Only clusters in which all single cells were visible were counted.

3.2.7 Western Blotting
Western blotting was performed as previously described (253). Antibodies used: p21Cip1 (BD
Biosciences, 610234), TP53 (BD Biosciences, 554293) and GAPDH (Cell Signaling, 5174).

3.2.8 Annexin V staining.
At the indicated time points, cells were harvested, washed with PBS, and resuspended in 100 μl of
1x Binding Buffer (AnnexinV-FITC apoptosis detection kit; 556547, BD Biosciences, NJ, USA)
with 5 μl of Annexin V and 5 μl of PI, then incubated at room temperature for 15 min in the dark.
This suspension solution was then brought up to 500 μl using the same buffer and then analyzed
by flow cytometry. Apoptotic cells express phosphatidylserine on the extracellular surface of the
plasma membrane and thus, amenable for binding with annexin V. PI is a nuclear stain that cannot
permeate the cell membrane of living cells. Cells stained with both annexin V and PI are late
apoptotic cells that have disrupted plasma membranes.

3.2.9 TUNEL assay
For the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, adherent
cells were harvested and centrifuged at 10,000 rpm for 5 min onto slides (Shandon Cytospin 4,
Thermal Electron Corp) 48 h after etoposide removal. Slides were fixed with 4% formaldehyde
for 10 min and then washed with PBS for 5 min at room temperature. The cells were then fixed
with a 1:2 dilution of acetic acid and ethanol for 5 min, followed by staining with a 1:1000 dilution
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of DAPI at room temperature. Coverslips were sealed using clear nail polish and apoptosis was
assessed by evaluating three fields per condition with an Olympus inverted microscope (20x
objective, Q-Color3™ Olympus Camera, 488 nm filter and UV light, Olympus, Tokyo, Japan).
TUNEL assay detects DNA fragmentation, a process that is frequently associated with apoptotic
cells.

3.2.10 Cell cycle analysis
Cells were harvested, washed with cold PBS, then resuspended in a propidium iodide solution [50
μg/ml PI, 4 mM sodium citrate, 0.2 mg/ml DNase-free RNase A, and 0.1% Triton-X 100] for 1 h
at room temperature, while being protected from light. Before analysis, NaCl was added to the cell
suspensions to achieve a final concentration of 0.20 M. The cell suspensions were then analyzed
by flow cytometry.

3.2.11 qRT-PCR.
H460 cells were exposed to etoposide (1 µM) for 24 h and then harvested at the indicated time
points. Total RNA was isolated from the cell pellets following the manufacturer’s instructions with
the RNeasy kit (QIAGEN, Germany). cDNA samples from different cancer cell lines were
synthesized from the same starting material of total RNA following the manufacturer’s instructions
(ExiLERATE LNA™ cDNA synthesis kit, Exiqon, Germany). All samples were amplified in
triplicates using SYBR® Green probes from Exiqon in an ABI-7900HT model of real-time PCR
machine (ExiLERATE LNA™ qPCR, SYBR® Green master mix kit). Primers were purchased
from Exiqon.
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3.2.12 Animal Studies
NOD/SCID/Ifrg2r-/- (NSG) mice were purchased from Jackson laboratory and housed under
pathogen-free conditions according to the Virginia Commonwealth University IACUC guidelines.
To test for recovery potential of senescent cells, enriched high-C12FDG-positive H460 cells
(1×106) were suspended in PBS and injected into both the right and left flanks of 6-8 week old
male NSG mice (n=6). Tumor volume was measured every two days with calipers (tumor volume
was calculated using the following equation: V = length × width 2 × 0.5).
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3.3 Results
3.3.1 Etoposide induces senescence in H460 NSCLC cell line.
Our initial goal is to establish an experimental system where we establish a stable senescence
response in tumor cells using cancer chemotherapy. As discussed earlier, this experimental effort
will be focused in H460 NSCLC cells using the topoisomerase II poison. Utilizing different
treatment regimens, etoposide was able to induce a senescent growth arrest marked by increased
expression of SA-β-gal enzyme and development of characteristic morphological features
(enlargement, flattening and vesiculation) (Figure 3.1). These regimens included (i) a single
etoposide exposure for 24 hours at 1 μM concentration, (ii) a single etoposide exposure for 24
hours at 8.7 μM concentration (which represents a clinically relevant concentration) (iii) five
exposures to etoposide at 1 μM concentration each for 24 hours and every 5 days and (iv)
continuous exposure for 7 days. Using this screening, we decided to utilize the 1 μM concentration
for the majority of the studies in this project since it extensively induced senescence (SA- β-gal
expression) in the H460 cell line with minimal cell death as identified by TUNEL assay and
Annexin/PI staining (Figure 3.2). This allowed us to establish a model where senescence is the
primary response to treatment.
In addition to increased SA- β-gal expression and the characteristic morphology, etoposide
exposure induced other senescent hallmarks. First, etoposide exposure resulted in increased
formation of phosphorylated H2AX (γH2AX) and 53BP1 foci indicative of the formation of DNA
double stranded breaks and the activation of the DDR (Figure 3.3A). Etoposide-induced DNA
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Figure 3.1. Upregulation of SA-β-gal in H460 cells following etoposide exposure. Parental H46o cells are
round, small and grow in cauliflower-shaped colonies. Control H460 cells show little or no SA-β-gal staining
when cultured at subconfluent densities. After etoposide exposure, H460 cells exhibit a large, flattened
morphology and develop increased SA-β-gal expression which is evident by the blue staining in this figure.
Different etoposide concentrations or treatment regimens resulted in the induction of SA-β-gal. All images were
taken at the same magnification using 20x objective and bright field microscopy.

Figure 3.2. Exposure to etoposide (1 μM) results in minimal apoptosis. A. TUNEL assay shows minimal
staining for apoptosis 72 hours after etoposide (ETO, 1 μM) exposure in H460 in comparison with control. B.
Annexin V/Propidium iodide (PI) staining of H460 cells at 72 hours after etoposide (1 μM) exposure. Cells in Q1
are PI positive and reflect cells with disrupted plasma membrane. Cells in Q4 are annexin V positive and reflect
cells that have flipped phosphatidylserine on their outer membrane i.e., early apoptosis. Cells in Q2 are positive
for both stains and described as late apoptotic.The bar graph shows a quantification of the percentage of apoptotic
cells in comparison to SA-β-gal positive cells following etoposide treatment suggesting that senescence is the
predominant response.
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double stranded breaks were detected as soon as 6 hours of exposure and persisted for 12 hours
which was followed by repair leaving residual persistent damage (Figure 3.3B). Activation of the
DDR resulted in the induction of the p53ـــــp21Cip1 axis as marked by the increased expression of
p21Cip1 at the message and protein levels (Figure 3.3C). Due to homozygous deletion of the
CDKN2A gene that encodes for the CDKI p16INK4a in H460 cells it appears that the etoposide
growth arrest in these cells is primarily mediated by p21Cip1 (264). p21Cip1 is capable of enforcing
a stagnant growth arrest as part of senescence induction by inhibiting critical CDKs required for
progression in the cell cycle. Accordingly, within 24 hours following etoposide exposure, most
H460 cells arrested with a G2 DNA content (Figure 3.4A). This growth arrest was evident by the
inability of etoposide-treated cells to proliferate and form colonies in comparison to the rapidly
growing control cells that were not exposed to etoposide (Figure 3.4B).
Next, we tested whether etoposide resulted in gene expression alterations. After 72 hours of
etoposide exposure, the expression of a number of SASP components was significantly increased.
Specifically, the expression of IL-1β and IL-8 as well as CXCL1 (Figure 3.5A). Interestingly, the
results of three independent experiments failed to show an increase in the expression of IL-6
following senescence induction by etoposide. Despite the fact that IL-6 is a frequent component
of the SASP, the variability in gene expression between different cell lines is common as it appears
that SASP can have multiple signatures (75). Finally, we monitored histone modifications that
reflect epigenetic modulations that are closely associated with senescence, namely, H3K9Me3.
H3K9Me3 marks focal condensation of chromatin, which when associated with senescence is
collectively named SAHF. Etoposide resulted in the formation of numerous H3K9Me3 foci in
H460 cells (Figure 3.5B).
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Figure 3.3. Exposure to etoposide (1 μM) activates the DDR. A. Wide-field fluorescent microscopy images of
both γH2AX and 53BP1 6 hours following etoposide exposure (ETO, 1 μM). All images were taken at the same
magnification using a 100x oil immersion objective. Nuclei are stained with DAPI. B. Quantification of γH2AX
staining using flow cytometry over time after etoposide exposure. C. qRT-PCR quantification of the expression
level of p21Cip1 72 hours in H460 cells following etoposide exposure. Statistical analysis was performed by oneway ANOVA with Tukey post-hoc test. **p<0.01 D. Western blot demonstrating the increased protein level of
p21Cip1 72 hours in H460 cells following etoposide exposure.
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Figure 3.5. Changes in gene expression of SASP factors and SAHF formation. A. qRT-PCR quantification of
the expression of multiple Senescence-associated Secretory Phenotype (SASP) factors (IL-1β, IL-8 and CXCL1)
in H460 at day 1 after etoposide (1 µM) exposure. Data are expressed as mean ± standard error of the mean (SEM).
Statistical analyses were performed by one-way ANOVA with Tukey post-hoc test. **p<0.01, ***p<0.001,
****p<0.0001. B. Immunofluorescent staining of H460 cells showing the formation of H3K9Me3 foci (red).
H3K9Me3 images were obtained by confocal microscopy (63x objective).
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Collectively, etoposide effectively induced senescence in H460 cells based on suppressed
proliferation, cell cycle arrest, activation of the DDR, upregulation of SA-β-gal, SASP induction
and formation of SAHF.

3.3.2 Etoposide-induced senescence in H460 NSCLC cells is followed by
proliferative recovery.
To evaluate the growth pattern of etoposide-treated H460 cells that exhibit senescence features,
we monitored their growth temporally. After etoposide exposure, H460 underwent growth arrest
initially as expected, but that growth arrest was not durable i.e., it was followed by restoration of
growth capacity which we refer to as proliferative recovery (Figure 3.6A). Furthermore, the
recovering cells were able to generate colonies after days of senescence-associated growth
abrogation (Figure 3.6B). We also observed a similar growth pattern using the multiple treatment
regimens with etoposide (1 μM) as well as the near-clinical plasma concentration of etoposide (8.7
μM) (Figure 3.6C and D). These observations suggests that the etoposide-induced growth
inhibition is not terminal despite the induction of multiple senescence markers in the majority of
the treated cells.
To determine if the change in growth pattern was accompanied by alteration in the senescent
phenotype, we assessed the expression of several senescence markers over time following the
removal of etoposide. First, to obtain an objective assessment of the number of senescent cells, we
utilized the SA-β-gal fluorescent substrate, C12FDG, which allows for: (i) microscopic
identification of SA-β-gal positive cells where other senescence labels can be combined. For
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Figure 3.6. Proliferative Recovery after etoposide exposure. A. Growth arrest and recovery of H460 and
exposed to etoposide (1 µM) for 24 h (day 0) as determined by the number of viable cells measured at the indicated
time points by trypan blue exclusion. B. Recovery of colonial proliferation after etoposide-induced growth arrest
in H460 cells. C and D. Growth curves of H460 cells exposed to etoposide at the indicated concentrations. In C,
H350 cells were exposed to etoposide 5 times (X5) each for 24 hours.
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example, both SA-β-gal and p21Cip1 or H3K9Me3 expression can be evaluated simultaneously, (ii)
flow cytometry based quantification of the SA-β-gal positive senescent cells. Following etoposide
treatment, as presented previously, H460 cells upregulated SA-β-gal and express higher levels of
p21Cip1 (Figure 3.7A). Using flow cytometry, we were able to quantify the percentage of SA-βgal positive senescent cells over time. The initial upregulation of SA-β-gal at day 1 and 3 after
etoposide treatment was followed by a gradual decline in expression levels back to control levels
by day 7, which coincides with proliferative recovery (when the cells start to grow back) (Figure
3.7B).
Next, we evaluated the cell cycle distribution over time; the number of cells arrested with a G2
content within 72 hours of etoposide treatment was gradually decreasing, suggestive of resolution
of the growth arrest (Figure 3.7C). Furthermore, proliferative recovery was accompanied by a
gradual decrease in the expression of p21Cip1, consistent with the resolution of the growth arrest
(Figure 3.7D and E). Finally, monitoring the expression levels of IL-1β, IL-8 and CXCl1, the
expression of SASP was also declining over time as the cells were recovering proliferation.
Collectively, these results suggest the gradual resolution of the senescence phenotype in H460
cells induced into senescence by etoposide.

3.3.3 Evidence for proliferative recovery based on SA-β-gal enrichment
and live cell microscopy.
Proliferative recovery from senescence growth arrest by H460 and HCT116 (BTG1-RFP) cells
was further monitored by staining with crystal violet and C12FDG. Cells reverted from an enlarged,
highly-vesicular (abundant cytoplasmic granules) morphology to a more round, smaller
phenotype; the cells further demonstrated reduced C12FDG staining (Figure 3.8). However, one
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Figure 3.7 Proliferative recovery from etoposide treatment of H460 and HCT116 cells is associated with
resolution of some senescence-associated features. A. Confocal microscopy and immunolabeling for p21Cip1
(red) and C12FDG (green) (63x objective) after etoposide (1 µM) exposure in H460 cells. B. Flow cytometry
quantification of senescence based on C12FDG staining (SA-β-gal positive cells) over the indicated time points
after etoposide (1 µM) exposure suggestive of senescence induction and resolution. C. Cell cycle distribution of
H460 cells after etoposide (1 µM) exposure at the indicated time points. D. qRT-PCR quantification of the
expression of p21Cip1 message and Western blotting of both p53 and p21 Cip1 in H460 cells following etoposide (1
µM) exposure at the indicated days. E. qRT-PCR quantification of the expression of multiple Senescenceassociated Secretory Phenotype (SASP) factors (IL-1β, IL-8 and CXCL1) in H460 following etoposide (1 µM)
exposure. Data are expressed as mean ± standard error of the mean (SEM). Statistical analyses were performed by
one-way ANOVA with Tukey post-hoc test. **p<0.01, ***p<0.001, ****p<0.0001.
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interpretation of the previous data could be that the proliferating cells were not derived from the
senescent-like population, but were derived from cells that escaped the full effect of etoposide
treatment and were not detected until they achieved a critical mass. To address this potential
drawback to our studies, cells induced into the senescence by etoposide were labeled with C12 FDG
followed by flow cytometric cell sorting and subsequent reseeding of the highest C12FDG-positive
(SA-β-gal positive) subpopulations. Enrichment was followed by post-sorting confirmation by
analyzing C12FDG staining of the purified population and then single cell phenotypic validation
using imagery flow cytometry and labeling for additional senescence markers (SA-β-gal, p21Cip1
and γH2AX) (Figure 3.9).
As was observed for the heterogeneous population generated in response to etoposide treatment,
these highly C12 FDG-positive H460 cells were also able to recover proliferative capacity (Figure
3.10A). Additional studies were designed to evaluate the capacity of senescent-like cells that
maintained prolonged SA-β-gal activity (essentially a sustained senescence) to recover
proliferative capacity. High C12FDG-positive H460 cells (enriched for senescence at 7 days
following etoposide exposure) were also able to recover proliferative capacity (Figure 3.10B).
These highly C12FDG-positive cells also demonstrated the capacity for colony formation in a cell
density-dependent manner (Figure 3.10C). As might have been anticipated, a large proportion of
these senescence-sorted cells remained in a growth-arrested state for days following enrichment,
indicating that only a subpopulation of senescent cells re-emerges from the growth-arrested state
(Figure 3.10D).
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Figure 3.8. The recovering population from etoposide treatment of H460 cells resembles parental cells.
Upper panel: Crystal violet staining after senescence induction in H460 cells (on days 3, 5 and 7). Lower panel:
C12FDG staining (SA-β-gal on days 3, 5, and 7.) Arrow heads point to the recovering population. (20x objective).
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Figure 3.9 Post-enrichment validation of sorted H460 cells. A. Flow cytometry profile for H460 cells before
and after enrichment. Cells were then harvested under sterile conditions and enriched based on the gating for cell
size and C12FDG staining using BSC Aria- BD FACSAria™ II High-Speed Cell Sorting. Purple histogram is
reflects the profile of C12FDG staining in etoposide-treated H460 cells prior to enrichment, while the three green
histogram are for three representative samples of the profile of C12FDG staining following enrichment. B. Postenrichment analysis of control, etoposide- treated pre-sorted and sorted H460 cells showing C12FDG staining using
AmnisImageStreamX Mark II™ flow cytometry C. Confocal microscopy images of high-C12FDG-positive H460
cells following enrichment, showing C12FDG staining, p21Cip1 and γH2AX. Scale bar: 20 µm.
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To definitively distinguish tumor cells that might have initially evaded etoposide-induced
senescence from cells that developed a senescence-like state, but recovered proliferative (selfrenewal) capacity, the sorted high C12FDG-positive H460 population was reseeded and monitored
by live cell imaging using phase contrast microscopy. The temporal response after etoposideinduced senescence was found to be quite heterogeneous. Over the period of observation (40
hours), the majority of the senescent cell population persisted in a growth-arrested state, while a
few cells appeared to undergo apoptosis (or possibly mitotic catastrophe). However, occasional
hypertrophic, flattened cells that had remained in an arrested state were found to be capable of
recovering the ability to divide; Figure 3.10E shows representative images of the monitored
population over the indicated time periods which illustrates spontaneous mitotic events (tracked
by arrow heads). Taken together, these results indicate that only a subpopulation of senescent cells
re-emerges into a proliferative state.
As a complement to the real-time imaging studies presented in the previous section, we utilized
High Speed Live Cell Interferometry (HSLCI) to evaluate changes in biomass kinetics and single
cell area in response to etoposide. HSLCI uses interferometric microscopy to perform rapid optical
biomass measurements to quantify cellular response to drugs (263). LCI has been previously used
to profile drug-induced growth arrest with picogram sensitivity and drug profiling in melanoma
and breast cancer models (263,265,266). Like other quantitative phase imaging techniques, HSLCI
is non-invasive with no fluorescence or dye labeling (263). Figure 3.11A shows a cluster of three
cells exhibiting a classic senescence-like phenotype with quite extensive morphological changes,
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Figure 3.10 Proliferative recovery of enriched senescent H460 cells. A and B. Growth curves for high-C12FDGpositive H460 (enriched on day 3 and 7 cells after flow cytometry enrichment. X axis indicates time points relative
to etoposide (1 µM) exposure. C. Colony forming assay showing cell-density dependent restoration of growth of
high-C12FDG-positive H460 cells. D. Representative images of the recovering high-C12FDG-positive H460 cells
showing variable cell fates. (Scale bar: 200 μm) E. Time-lapse live-cell microscopy of H460 high-C12FDGpositive cells performed for 40 h at 5 days following flow cytometry enrichment. Arrows indicate mitotic events.
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specifically flattening marked by increased cell area and mass without division (lower panel of
Figure 3.11A). To investigate this observed change in single cell size at a population level, mass
and area measurements of control and etoposide-treated single cells were taken on day 4 post
etoposide exposure (Figure 3.11B).

The etoposide-treated cells were comprised of a

heterogeneous population that differed markedly in mass and area, consistent with the
heterogeneous response to drug exposure suggested by the previous experiments. As can be seen
in the population histograms (Figure 3.11C), a subpopulation of cells in the etoposide treated
group remained the same size as control cells while the majority of the population increased in
size and area. For example, in the same image in Figure 3.11B of the etoposide treated, but
unsorted population, cell b has a mass and area of 853 pg and 423 um2, respectively, which is
comparable to control cell a (618 pg, 207 um2) while (senescent) cell c has a mass of 4981 pg and
an area of 2646 um2. (Figure 3.11B).
Flow cytometry based enrichment for SA-β-gal coupled to HSLCI, generated a profile of mass
and area for the different populations. Representative example cells of the low C12 FDG population,
cell d (727pg, 279 um2), and high C12FDG population, cell e (2515 pg, 2250 um2), reflected the
observation that the high-C12FDG cells increased in size while the low C12FDG maintained the
size of control cells despite treatment with etoposide. Table 2 provides a summary of the median
mass and area for control cells, unsorted cells after etoposide treatment, and high and low C12FDG
populations. On a population level, control cells had a median mass of 917 +/- 79 pg and a median
area of 431 +/-71 um2 while the mass of unsorted etoposide-treated cell population had a median
mass and area of 1799 +/-149 pg and 1355 +/-117 um2, respectively (p<0.001, Figure 3.11C).
High- C12FDG cells (i.e. after sorting) had a median mass of 2491+/- 171 pg, and median area per
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Figure 3.11. HSLCI analysis of etoposide-treated H460 tumor cells shows increases in mass and area, and
division of high-C12FDG cells. A. HSLCI biomass images of the cluster pictured. This cluster is three cells that
do not grow in number over a period of three days after etoposide treatment while exhibiting increase in mass and
area over time. The corresponding change in mass and area of each cell labeled A, B, and C over time is in the
inset table below the images. All scale bars are 45 um. B. At day 4 post treatment, the cell population exposed to
etoposide (n=447) had a mixed population with some single cells with higher mass, and larger area per cell as
compared to the control population (n=272) while others maintained similar sizes to control population. In a
separate experiment, etoposide treated cells were sorted into verified senescent-like (high-C12FDG) and nonsenescent (low-C12FDG) populations prior to HSLCI measurement. Senescent-like high-C12FDG cells (n=505)
were more massive and larger on average than non-senescent low-C12FDG cells (n=199) which had similar size
to the control population. C. The single cell mass and single cell area of etoposide treated (n=447) and C12FDGhigh cells (n=505) were significantly larger than vehicle (n=272) or C12FDG-low (n=199) (C) cells. Letters refer
to the locations of cells from figure 5 in the histograms. D and E. examples of two large etoposide-treated,
enriched high-C12FDG cell which divides over day 4-6 and 4-9 after etoposide treatment, respectively. Cell g’s
progeny are circled in orange. All scale bars are 45 um. Red outlines indicate clusters that were tracked.
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cell of 1683 +/- 131 um2, while in the low-C12FDG population of cells, median mass was 1386 +/147 pg and median area was 627 +/- 99 um2 (p<0.001, Figure 3.11C). These observations indicate
that etoposide treatment results in a dramatic dysregulation of cellular biomass; the majority of
cells are large in size consistent with the cellular flattening that characterizes the senescence-like
phenotype, while the minority of cells that maintain biomass regulation (i.e. that do not enter into
senescence after exposure to etoposide) have low-C12FDG expression (Table 2).
The senescence enriched etoposide-treated cells gained biomass slowly, occasionally followed by
cell division. Two examples of large, SA-β-gal positive cells dividing are shown in Figure 3.11D
and E. The mass and area of the single cells shown to divide are, prior to division, much greater
than single cells measured in the control or low-C12FDG populations (Figure 3.11D and E). For
example, the masses of cells f (3519 pg) and g (2245 pg) are four and two standard deviations from
the mean of control cell mass respectively. Similarly, the areas of f (2133 um2) and g (1495 um2)
are over three standard deviations of the mean control cell area. Similar to the decline in SA-β-gal
activity as proliferative recovery progress, the progeny of cell g lose the classic enlarged senescent
phenotype as cells become smaller in consecutive generations (Figure 3.11E). Collectively, these
data demonstrate that senescent-like H460 cells undergo spontaneous divisions at a single cell
level, indicating that SA-β-gal-positive enriched, senescent-like cells are not terminally arrested
and can resume mitotic proliferation.
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Table 2. HSLCI biomass and area measurements of pre and post sorted H460 cells. Post sorting highC12FDG cells (n=505) exhibit higher mass and area than the post-sorted low-C12FDG cells (n=199) and the presorted etoposide-treated cells (n=447).
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3.3.4 SA-β-gal positive cells have the potential to form viable tumors in a
mouse model.
To determine whether senescent-like cells have the capacity to generate tumors in vivo, enriched,
high C12FDG-positive H460 cells were subcutaneously injected into NOD/LtSz-scid IL2R gamma
null (NSG) mice. Within approximately 2 weeks of injecting a senescence-enriched tumor cell
population, these mice showed evidence of tumor development (Figure 3.12).
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Figure 3.12. SA-β-gal positive cells have the potential to form viable tumors in a mouse model. Tumor
formation following transplantation of senescence-enriched H460 cells in NSG mice (n=6), indicating their ability
to form proliferating tumors in vivo. Data are expressed as mean ± standard error of the mean (SEM).
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3.3.5 Recovery from etoposide-induced senescence in HCT116 CRC
cancer cells.
In parallel with the studies in the H460 NSCLC cell line, we have utilized a similar experimental
approach in HCT116 colorectal cancer cells exposed to etoposide. HCT116 cells were obtained
from Dr. Igor Roninson’s laboratory at the University of South Carolina which were derived by
lentiviral transduction of HCT116 cells with the construct expressing dsRed from the promoter of
BTG1 gene (RFP-BTG1). BTG1 (B-cell translocation gene-1) is a tumor suppressor gene that
possesses multiple antiproliferative and cell cycle regulatory functions (267). BTG1 has been
identified as a marker of senescence based on microarray analysis of alteration in gene expression
following the exposure of tumor cells to doxorubicin (262). Moreover, the association between
senescence and BTG1 was independent to cell cycle regulators such as p53 or p21 Cip1 suggesting
that it is regulated separately (262). The expression of BTG1 was also shown to be associated with
senescence induced by doxorubicin in HT1080 osteosarcoma cells (data not shown). Here we
utilize BTG1 as a surrogate for senescence and an additional marker to enrich for chemotherapyinduced senescent cells.
First, BTG1 expression is increased in cells that also upregulate SA-β-gal in response to etoposide
exposure, indicative of both senescence induction and the association of BTG1 with senescence in
HCT116 cells (Figure 3.13A). Similar to our observations in the H460 cells, etoposide-treated
HCT116 (BTG1-RFP) cells undergo a senescent growth arrest followed by proliferative recovery
which was also observed within 5-7 days following treatment (Figure 3.13B). While the BTG1
reporter construct is strongly expressed initially following etoposide treatment, its expression
declines gradually over time, again suggesting reversal of senescence. This reversal of senescence
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is accompanied by a generally similar pattern in the cell cycle profile, as well as in the expression
levels p21Cip1 and other components of the SASP (Figures 3.13C, D and E). Here, IL-1β and IL8 expression was significantly increased at Day 3 after drug exposure and, similar to the data
generated in the H460 cells, gradually declined over time. While IL-6 levels did not change
(similar to H460 cells), CXCL1 expression was initially increased in association with senescence
followed by a gradual decline.
Similar to the H460 cells, a single-cell enrichment protocol was utilized to isolate highly senescent
cells after etoposide treatment. Again, enrichment involved rigorous gating for the highest 30% of
the C12FDG–positive (SA-β-gal-positive) and enlarged cells, in addition to the expression of RFPBTG1. The dual expression of C12FDG and RFP-BTG1 was confirmed post-sorting (Figure
3.13F). Enriched HCT116 cells were monitored in culture and found to regain proliferative
capacity in a similar fashion to enriched H460 cells (Figure 3.13G). Collectively, this evidence
shows that etoposide-induced senescence is not obligatorily permanent in another tumor cell
model.
A
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Figure 3.13. Proliferative recovery from etoposide-induced senescence in HCT116 cells. A. Wide-field
fluorescent microscopy of BTG1-RFP (red) and C12FDG (green) in HCT116 cells after etoposide (1 µM) exposure.
Scale bar: 20 µm. B. Growth arrest and recovery of HCT116 (BTG1-RFP) cells exposed to etoposide (1 µM) for
24 h (day 0). C. Flow cytometry analysis of BTG1-RFP expression over time following etoposide (1 µM)
exposure. D. qRT-PCR quantification of the expression of p21Waf1/Cip1 and multiple senescence-associated
secretory phenotype (SASP) factors (IL-1β, IL-6, IL-8 and CXCL1) over time following etoposide (1 µM)
exposure. Data are expressed as mean ± standard error of the mean (SEM). Statistical analyses were performed by
one-way ANOVA with Tukey post-hoc test. *p<0.05, ** p<0.01, ****p<0.0001. E. Widefield fluorescent
microscopy images of HCT116 (BTG1-RFP) cells following enrichment showing both RFP and C12FDG staining.
Scale bar: 200 pixel. G. Growth curves for C12FDG/RFP- dual positive HCT116 (BTG1-RFP) cells after flow
cytometry enrichment. X axis indicates time points relative to etoposide (1 µM) exposure.
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3.4 Discussion
A long-standing paradigm in the scientific literature has been that senescence is an irreversible
form of growth arrest (24,268). However, a number of previous reports in the literature, including
work from our own laboratory, have suggested that some subpopulations of cells demonstrating
characteristics of senescence have the potential to recover proliferative capacity by escaping or
reverting from the senescent state (26,89,212,213,216,220,269,270). Consequently, in addition to
the overall heterogeneity of tumor cell response to chemotherapy and radiation that can involve
different modes of cell death such as apoptosis, necroptosis, ferroptosis, mitotoic catastrophe and
a cytotoxic form of autophagy, as well as conventional growth arrest (251,252), and growth arrest
mediated by autophagy and senescence (253), it appears that cells that express markers of
senescence may also demonstrate heterogeneous responses (75). What we observe in our real-time
imaging work is that while some cells that appear to be senescent remain in a prolonged state of
growth arrest, senescent cell retain the capacity to re-emerge into a proliferative state.
In addition to the heterogeneity observed in the real-time imaging studies of cells enriched for
senescence, our high-speed live cell interferometry (HSLCI) confirmed that the arrested cells
exhibited increased cell mass and area consistent with cellular senescence(271). Furthermore, the
ability of cells induced into senescence to form tumors was established in immune deficient mice.
In this context, studies of the contribution of the immune system to the recognition and elimination
of cells induced into senescence by chemotherapy and radiation are in progress.
The HSLCI technology, as applied in the current work, provides a novel perspective on the growth
kinetics of tumor cell lines, specifically the relationship between cellular proliferation rate and the
mass - area. The control cell lines and the subpopulation of etoposide treated cells that does not

91

undergo senescence-like changes exhibit high proliferation rates, while maintaining similar
morphologies and similar mass and area. That is, under normal circumstances, cells do not grow
beyond a certain mass-area without division being triggered. However, the etoposide-treated cells
demonstrating senescence apparently have this relationship of proliferation with mass-area altered
such that the cells continue to gain mass and grow in area without proliferation being triggered.
However, this is not an indefinite process. While the bulk of the senescent cells remain in a growth
arrested state, consistent with the paradigm that senescence is “irreversible”, subpopulations of the
senescent cells recover proliferative function.
Although the factors that allow for division of this subset of cells expressing senescence markers
are ongoing, it has been suggested that these cells may acquire stem cell characteristics (90). Many
tumor cells develop a high degree of genomic instability and eventually inactivate or otherwise
lose the function of tumor suppressor genes such as p53 and p16INK4a, which are regulatory
elements of senescence (272,273). We further cannot predict whether the cells that have escaped
from the senescence-like state will indefinitely maintain replicative capacity for subsequent
generations, or will ultimately die. However, previous studies have suggested that the recovering
cells may be more aggressive than the parental cell population (219). Furthermore, the capacity of
cells derived from the senescent population to form tumors in animals suggests that tumorigenic
potential is maintained. Here, it should be noted that we have also observed a similar capacity of
breast tumor cells induced into senescence by doxorubicin to form tumors (a separate project in
the lab).

Efforts to identify the factors that distinguish irreversibly arrested senescent cells from senescent
cells that generate proliferating progeny are under way. We postulate that senescence that is
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capable of giving rise to actively dividing cells could represent one previously unrecognized form
of tumor dormancy; furthermore, cells that arise from the senescent-like state and re-emerge into
a proliferative state could also ultimately contributes to disease recurrence.

There is strong evidence of senescence induction in the tumors of patients that have received
chemotherapy or irradiation (58,93). In one study, senescence induction following neo-adjuvant
chemotherapy was associated with a poor outcome in cancer patients(168). This effect might prove
to be linked to the SASP, which has been suggested to contribute to adverse effects of therapy,
poor outcomes, and possibly disease relapse (274). A direct clinical correlate of the model reported
here is the emergence of therapy induced acute myelogenous leukemia in patients undergoing
treatment with etoposide (and other topoisomerase II inhibitors). These patients typically present
with rapidly progressive disease bearing translocations of the mixed lineage leukemia (MLL) gene,
with multiple translocation partners. It is known that the hematopoietic progenitors develop DNA
damage in response to topoisomerase II inhibitors, and that they present with a latency of 1-2 years
following chemotherapy exposure (275,276). Based on the findings reported in this work, it may
be postulated that these progenitors develop a senescent state in the immediate aftermath of
chemotherapy, from which they recover with MLL and possibly other genetic lesions once the
chemotherapy is stopped. Eventually those progenitors with genetic lesions conducive to survival
of the transformed cells develop full blown hematological malignancy. Collectively, this growing
evidence strongly suggests that the induction of senescence in tumors of patients receiving
chemotherapy is not necessarily a beneficial outcome of therapy.
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3.5 Future studies
Despite successfully providing evidence on the ability of senescent tumor cells to recover, it is
recognizable that further work is required to expand on these observations. First, the changes that
accompany recovery from senescence need further investigation. This requires molecular
characterization of the recovered senescent population in comparison to the parental cell line,
primarily, changes in gene expression profiles. Furthermore, recent evidence has suggested that
cell populations originating from senescence acquire more aggressive traits (90,219); therefore,
assessment of the differences in invasive, migratory and response to therapy of the recovered
population needs further study. The development of more malignant phenotypes that respond
poorly to conventional therapy is another indication that senescence could be a major component
of tumor dormancy since recurrent cancer is refractory to most treatments. Finally, this approach
should assist in identifying signaling pathways that facilitate the recovery of senescent tumor cells.
This requires single cell analysis of senescent tumor cells to discover molecular signatures that
could help in the prediction of recovery from senescence, given that only a subpopulation of
senescent cells is capable of escaping.
Senescent cells are removed from the body by immune cells (237). In this work we have
demonstrated the ability of senescent tumor cells to recover in vivo in an immunocompromised
animal. This observation provides the incentive for investigating the ability of senescent cells to
recover from senescence in an immunocompetent animal, where the immune cells could either
eliminate or keep senescent cell in check. Moreover, it is important to determine if the recovered
cells acquire the ability to escape immunosurveillance, a question that has not yet been addressed
so far. Again, these expectations further support the premise that senescence is a form of tumor
dormancy.
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Ultimately, an experimental model of tumor dormancy following chemotherapy and based on
senescence could be developed. For that, we suggest designing an animal model where senescent
cells accumulating following the administration of chemotherapy can be tracked in vivo. This
requires the labeling tumor cells with fluorescent labels integrated with one or more senescence
markers and complemented with in vivo bioluminescence imaging. Moreover, development of a
transgenic tumor cell line based on the suicide gene approach should be ideal to study the effect
of eliminating these senescent cells on the likelihood of recurrent metastasis development. Suicide
gene models rely on the ability of an inert compound to induce cell death in cells that become
sensitive based on the expression of certain markers, such as the expression of p16INK4a.
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Chapter Four: Interference with recovery of tumor cells
from a chemotherapy-induced senescent-like state by the
senolytic, ABT-263

4.1. Introduction
Senescence is a fundamental mechanism of aging and a powerful tumor suppressor mechanism
that prevents the replication of genomically unstable cells (149). Senescent cells accumulate both
in pre-malignant lesions and as a main component of tumor composition in patients (277).
Furthermore, as discussed earlier, senescence is induced in tumor cells as a consequence of both
DNA damaging and targeted cancer therapies, making senescence a primary response to cancer
treatment (159,203).

Although chemotherapy- and radiation-induced senescence have been

studied for decades, it remains uncertain how the senescent response contributes to (or interferes
with) disease control (278). Senescence has been proposed as a favorable outcome of cancer
treatment since tumor senescent cells are in a growth-abrogated phase that halt tumor proliferation.
Moreover, senescent cells can elicit an immunesurveillant response resulting in their clearance
from the body (279). Accordingly, development of novel therapeutics that can induce senescence
in tumor cells has been encouraged (166,203). This established opinion that senescence is a
desirable goal of therapy can be derived, for example, from studies where senescence was
associated with increased radiosensitivity in nasopharyngeal carcinoma cells, or where
overexpression of SA-β-gal was associated with a reduction in the recurrence of prostate cancer.
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However, this rationale has always overlooked the extensive genetic heterogeneity of tumor cells
as well as the transcriptomic cell-cell differences amongst a uniform senescent population
(75,197), thus, excluding the potential that the senescent growth arrest might not be obligatorily
permanent. So far, we have presented experimental evidence and similar observations from the
literature on examples where cells expressing the hallmarks of senescence re-entered a
proliferative state. In addition, there is a growing rationale that the accumulation of senescent cells
is negative for multiple reasons: (i) senescent cells are resistant to apoptosis and persist viable and
metabolically active in the body. This applies also to senescent tumor cells, thus, senescence might
provide means for cancer to remain dormant. (ii) The accumulation of senescent cells in the body
is associated with a chronic inflammatory state mediated by the SASP (85,280) which is implicated
in many other pathologies (281). More importantly, senescence, and the chemokines and cytokines
secreted as a consequence of the SASP have deleterious paracrine influence that promotes several
adverse effects associated with conventional chemotherapy including relapse (274). In addition, a
pro-tumor SASP response could lead to a suppressed immune response and the maintenance of
dormant tumor cells (282–284). (iii) Finally, recent studies have reported that cells derived from a
senescent tumor population are often more aggressive than the original population which would
be consistent with the difficulties encountered when treating recurrent cancer (90,219).
Collectively, these recent updates indicate that senescence is an initially favorable response to
therapy by delaying tumor progression, but an ultimately deleterious therapy outcome.
Recent efforts have shown that the removal of senescent cells from aging animals delays the onset
of several aging-associated phenotypes and ameliorates already established pathologies (241,285).
This approach, which was based on a genetic model of a p16INK4a suicide gene has been extended
to identifying novel molecules that can eliminate senescent cells in a similar fashion; such drugs
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are referred to as senolytic agents (243). These promising efforts have been largely restricted to
progeroid models (with little focus on senescent tumor cells) or to merely experimental therapies.
For example, an experimental cytotoxic drug delivery system based on the upregulation of SA-βgal cleared senescent tumor cells induced by the CDK4/6 inhibitor, palbociclib, and resulted in
dramatic tumor xenograft regression (286). In this context, a powerful model to eliminate
senescent cells is based on the use of the established Bcl-2 inhibitor ABT263 (navitoclax) which
was shown to clear senescent cells from animals subjected to total body radiation, resulting in
rejuvenation of their hematopoietic functions (76,287). ABT263 was also shown to improve
radiation-induced pulmonary fibrosis in a mouse model by eliminating senescent cells (288).
ABT263 is currently being tested in dozens of clinical trials making it already available in the
clinic. Although ABT-263 has impressive therapeutic effects as a monotherapy for lymphoid
malignancies (289), it has been recently been replaced with ABT-199, which is more selective
against Bcl-2, which is the major anti-apoptotic protein active in leukemias (290). ABT-263 is
now actively being tested for activity against solid tumors in combination with other
chemotherapies because of its ability to target BCLXL, another member of the Bcl-2 protein family
(www.clinicaltrials.gov).
While drugs such as ABT-263 are usually administered together with the chemotherapy(291), we
are proposing a novel therapeutic approach utilizing the senolytic potential of ABT263, in that,
once the tumor cells have entered into an established state of senescence, ABT263 shall be used
as a “clearing” agent to eliminate the residual senescent tumor cells in order to interfere with
disease recurrence (Figure 4.1). Given the sensitivity of senescent cells to senolytics, drugs such
as ABT-263 are also likely to be most effective following the use of chemotherapeutic agents that
either promote primarily senescence or that leave a residual surviving senescent cell population.
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In addition to ABT-263, several other senolytic agents have recently been identified, most
prominently the HDAC inhibitor panobinostat (292), and the HSP90 inhibitor 17-DMAG (293).
Each of these compounds is approved for use in investigational clinical trials either alone or in
concert with traditional chemotherapies (294,295). However, the most effective scheduling to
maximize their clinical benefits against solid tumors remains to be determined. It is possible that
drug efficacy would be maximized by treating patients when their tumors have achieved peak
levels of senescence (either as a primary response or in residual cells). This would reduce the total
exposure to senolytic agents, possibly allowing the use of effective lower doses, and for extended
periods of time.
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Figure 4.1. The use of senolytic therapy to eliminate senescent tumor cells. A model illustrating the proposed
therapeutic approach. Tumors exposed to conventional/targeted therapies accumulate senescent tumor cells that
persist after the end of treatment. These cells contribute to adverse effects of therapy and can contribute to cancer
relapse. Sequential administration of ABT263 and other senolytic agents results in the selective elimination of
residual senescent tumor cells and thereby tumor regression, delay in cancer recurrence and recruitment of an
immunosurveillant response.
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4.2 Experimental procedures
4.2.1 Cell Lines.
The A549 cell line was generously provided by Dr. Charles Chalfant (Virginia Commonwealth
University). The H460 and the HCT116 (WT and p21Cip1 knockout) cell lines were generously
provided by Dr. Richard Moran and Dr. Lisa Shock (Virginia Commonwealth University). Lewis
lung carcinoma (LLC) cells, which originated in the lungs of a C57BL mouse, were a generous
gift from the laboratory of Dr. Andrew Larner (Virginia Commonwealth University). A549, H460
and LLC cells were cultured in DMEM, while HCT116 cells were cultured in RPMI, all
supplemented with 10% (v/v) fetal bovine serum (SH30066.03, Thermo Scientific, MA, USA),
100 U/ml penicillin G sodium (15140–122, Invitrogen, CA, USA), and 100 μg/ml streptomycin
sulfate (15140–122, Invitrogen, CA, USA) at 37º C and 5% CO2. Cells were grown at
subconfluent cultures and passaged 3 times weekly.

4.2.2 Cell Viability and Clonogenic Survival.
Growth curves were determined by counting viable cells based on trypan blue exclusion at various
time points after the treatment. Cells were harvested using trypsin, stained with 0.4% trypan blue
(T8154, Sigma, MO, USA), and counted using a hemocytometer under light microscopy. The
assay is based on the fact that viable cells have intact plasma membranes and thus impermeable to
trypan blue. Colony forming assay measures the cell survival and the ability of cells to form viable
colonies. However, instead of classically seeding a low number of cells and allow for colony
formation, A549 cells were seeded in a heavy monolayer before being induced into senescence by
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etoposide. At the indicated time points, cells were harvested, washed with PBS and fixed with
methanol. Fixed cells were allowed to dry overnight and then stained with crystal violet (0.01%).

4.2.3 SA-β-galactosidase Staining.
Histochemical SA-β-gal labeling was performed as previously described by Dimri et al. (80).
Images were generated using bright field by Olympus inverted microscope (Olympus inverted
microscope IX70, 20x objective, Q-Color3™ Olympus Camera; Olympus, Tokyo, Japan). For the
in vivo SA-β-gal staining, the harvested tumors were immediately snap frozen in liquid nitrogen
and then infiltrated with sucrose solution (5%) at 4º C overnight. Next, the tumors were embedded
in O.C.T. compound (Sakura, 25608-930) and stored at -80 º C. Frozen sections were performed
in the Virginia Commonwealth University Microscopy Core using Thermo FSE cryostat. The
samples were then stained similar to fixed cells.

4.2.7 Western Blotting
Western blotting was performed as previously described (253). Antibodies used: Bcl-2 (Sigma,
B3170), Bcl-XL (Cell Signaling, 2764S), p53 (Santacruz, sc-126), p21Cip1 (BD Biosciences,
610234), Bax (Cell Signaling, 2772T), Bak (Cell Signaling, 6947S), Noxa, (Invitrogen,, MAI41000), Mcl-1 (Enzo, ADI-AAP-240F), (c-caspase (Cell Signaling, 9664S) and GAPDH (Cell
Signaling, 5174).

4.2.8 Annexin V staining.
At the indicated time points, cells were harvested, washed with PBS, and resuspended in 100 μl of
1x Binding Buffer (AnnexinV-FITC apoptosis detection kit; 556547, BD Biosciences, NJ, USA)
with 5 μl of Annexin V and 5 μl of PI, then incubated at room temperature for 15 min in the dark.
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This suspension solution was then brought up to 500 μl using the same buffer and then analyzed
by flow cytometry. Apoptotic cells express phosphatidylserine on the extracellular surface of the
plasma membrane and thus, amenable for binding with annexin V. PI is a nuclear stain that cannot
permeate the cell membrane of living cells. Cells stained with both annexin V and PI are late
apoptotic cells that have disrupted plasma membranes.

4.2.9 TUNEL assay
For the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, adherent
cells were harvested and centrifuged at 10,000 rpm for 5 min onto slides (Shandon Cytospin 4,
Thermal Electron Corp) 48 h after etoposide removal. Slides were fixed with 4% formaldehyde
for 10 min and then washed with PBS for 5 min at room temperature. The cells were then fixed
with a 1:2 dilution of acetic acid and ethanol for 5 min, followed by staining with a 1:1000 dilution
of DAPI at room temperature. Coverslips were sealed using clear nail polish and apoptosis was
assessed by evaluating three fields per condition with an Olympus inverted microscope (20x
objective, Q-Color3™ Olympus Camera, 488 nm filter and UV light, Olympus, Tokyo, Japan).
TUNEL assay detects DNA fragmentation, a process that is frequently associated with apoptotic
cells.
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4.3 Results
4.3.1 Elimination of senescent A549 NSCLC cells by ABT263.
To study the potential of ABT263 to eliminate senescent tumor cells, we established a system
using A549 NSCLC cells exposed to etoposide either continuously for a week (at 2 μM
concentration) or using short-term exposure to the near-clinical (8.7 μM) concentration. Both
treatment regimens resulted in the induction of a robust senescent response in A549 cells, marked
by extensive upregulation of SA-β-gal (Figure 4.2A). In addition, etoposide treatment resulted in
a stable growth arrest, as the cells halted growth during the treatment period and at least 2 weeks
afterwards.
Next, we exposed senescent A549 cells to increasing concentrations of ABT263. At the same time,
we exposed proliferating, non-senescent A549 cells to the same range of ABT263 concentrations.
For a drug to exert a senolytic activity, by definition, it should induce cell death selectively in
senescent cells, with no or little effect in non-senescent cells. ABT263 produced a concentrationdependent decrease in the survival of etoposide pre-treated A549 cells with almost no cytotoxic
effect on proliferating non-senescent cells (Figure 4.2B). This observation indicates that ABT263
produced selective elimination of senescent A549 cells consistent with its established role of
eliminating senescent fibroblasts in aging models.
We determined that the decrease in survival resulting from exposure of senescent cells to ABT263
is due to induction of apoptosis, as demonstrated by the significant increase in annexin 5 staining
and the cleavage of PARP, both representing classic apoptosis markers (Figure 4.2C and D).
Again, in agreement with the survival results, ABT263 produced only a marginal increase in
annexin V staining in proliferating, non-senescent A549 cells.
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Figure 4.2 Senescent A549 cells are amenable for clearance by ABT263. A. Images are for histochemical SAβ-gal staining indicating senescence induction following both treatments in A549 cells. B. Elimination of
senescence-like A549 tumor cells induced by etoposide (2 µM for 7 days) by multiple concentrations of ABT263
(48 h exposure). Figure also shows the effect of ABT263 on proliferating, non-senescent cells. C. Assessment of
apoptosis by annexin V staining in etoposide-treated cells over time indicating increased cell death only in the
senescent population after overnight (O/N) ABT263 exposure. D. Western blotting showing PARP cleavage in
senescence-like cells following ABT263 exposure.
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Because interfering with recovery from senescence would be an additional advantage of using
senolytics, we moved to test the effect of ABT263 on the temporal growth of A549 cells after
etoposide exposure. Again, we used an identical regimen where we expose cells to etoposide
followed by the addition of ABT263. ABT263 had no effect on the growth of parental, nonsenescent A549 over time (Figure 4.3A). Consistent with senescence induction, A549 cells
exposed to etoposide (either 2 μM or 8.7 μM) exhibited a stable growth arrest pattern that was
sustained for days even following the removal of etoposide from the culture medium (Figure
4.3B). The addition of ABT263 resulted in a dramatic decrease in cell viability in etoposide pretreated cells. This decrease in viability was due to the decreased number of SA-β-gal cells
following ABT263 exposure (Figure 4.3B). Interestingly, the small population of cells that
persisted after ABT263 treatment are SA-β-gal positive with morphological characteristic of
senescence, suggesting that a single bout of ABT263 is incapable of completely eliminating a
senescent population of tumor cells. Furthermore, this remaining senescent population gradually
undergoes proliferative recovery (Figure 4.3C).
In effort to interfere with proliferative recovery, we exposed the surviving population with a
sequential, second bout of ABT263 48 hours after the first exposure. The second dose of ABT263
resulted in a further decrease in cell number suggesting that the residual senescent population
remains sensitivity to ABT263 (Figure 4.4A). This result indicate that sequential exposures of
senescent tumor cells could interfere with proliferative recovery. As might have been anticipated,
the senolytic ability of ABT263 diminishes over time as the senescence-like state is resolved,
suggesting that ABT263 is most effective immediately after the induction of senescence (Figure
4.4B).
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Figure 4.3. Temporal growth curves before and after ABT263 exposure . A. Growth curves of proliferating,
non-senescent A549 cells exposed to ABT263 (2 µM). B. Growth curves of A549 cells after induction of
senescence by etoposide (2 µM or 8.7 µM) followed by ABT263 (48 h exposure). Red arrows indicate when
ABT263 was administered. X axis refers to days relative to etoposide exposure. C. Images for histochemical SAβ-gal staining before and after treatment of A549 cells to with ABT263 (2 µM).
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Figure 4.4. Interference with proliferative recovery of senescent A549 by two exposures to ABT263. A.
Growth curves of A549 cells after induction of senescence by etoposide (2 µM) followed by two doses of ABT263
(48 h exposure). Red arrows indicate when ABT263 was administered. X axis refers to days relative to etoposide
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µM).
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4.3.2 Senolytic activity of ABT263 in senescent A549 cells is mediated
by Bcl-XL

Cells respond to stressful stimuli by activating a tightly controlled machinery of signaling and
effector molecules that lead to cell death, or apoptosis. Apoptosis represents a fundamental defense
barrier against the accumulation of damaged cells and is an important homeostatic mechanism
(296). A classic example is the induction of apoptosis in skin epithelial cells developing UVinduced DNA damage, where failure of these cell to activate their suicide program contributes to
their transformation into squamous carcinoma of the skin (297). Accordingly, evasion of apoptosis,
or “resisting cell death”, despite harboring lethal mutations, represents an important hallmark of
cancer cells (298). Resistance to apoptosis develops due to derangements in its regulatory
pathways, namely imbalances in the interaction between pro- and anti- apoptotic molecules.
For years, a main focus of study in the biology of cancer was the B-cell lymphoma 2 (Bcl2) protein
family which plays a pivotal role in the regulation of apoptosis through the intrinsic
(mitochondrial) pathway (299). In healthy cells, complex interactions between members of the
Bcl-2 family maintain the integrity of the mitochondrial membrane, preventing the release of
apoptotic molecules from the mitochondria. This function is maintained by the “anti-apoptotic”
members of the family, namely, Bcl-2 itself, Bcl-XL, Bcl-w and Mcl-1. On the other hand, the
“pro-apoptotic” members are either activators, such as Bid and Bim, or effectors, such as Bax and
Bak, where the latter two are capable of dimerization or breaching the integrity of the outer
mitochondrial membrane, thus, initiating the cell death cascade. Bcl-2 and the other anti-apoptotic
molecules can directly interact with Bax and Bak to prevent the initiation of apoptosis.
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Accordingly, overexpression of Bcl-2 can facilitate the acquired resistance to cell death stimuli
that occurs during transformation. In fact, as was described soon after its identification, Bcl-2
mediates survival in hematopoietic cells allowing for other oncogenic drivers, such as c-myc, to
promote accelerated proliferation (300). Similarly, Bcl-XL has been established to have an
important role in promoting tumor progression and stemness, not only in hematologic
malignancies but also in melanoma and glioblastoma (301), while Bcl-w contributes to the
pathogenesis of multiple lymphoid cancers (302).
Interestingly, senescent fibroblasts which exhibit a unique resistance to apoptosis, fail to
downregulate Bcl-2 in response to stress, indicating a key role of members of the Bcl-2 family in
the stability of senescent cells (74). Furthermore, Bcl-2 is necessary to mediate the cell cycle arrest
induced by DNA damage or serum starvation in senescent fibroblasts (303). However, other
reports have indicated that senescent cells develop apoptosis resistance independently from Bcl-2
function, suggesting a complicated role of Bcl-2 family in senescence (73,304). Furthermore,
elimination of senescent IMR-90 human fibroblasts (induced by radiation, replicative exhaustion
or oncogene overexpression) was dependent on Bcl-XL and Bcl-w rather than Bcl-2 (76).
Interestingly, upon assessment of Bcl-2, Bcl-XL and Mcl-1 proteins in A549 cells exposed to
etoposide and undergoing senescence, Bcl-2 expression was not evident (Figure 4.5A). This
suggested the involvement of the other targets of ABT263 in mediating its senolytic activity in
senescent A549 cells. Thus, we attempted to silence the other target og ABT263, Bcl-XL, using
short interfering RNA (siRNA) immediately after the removal of etoposide from the culture
medium (similar to when we add ABT263) (Figure 4.5B). Bcl-XL knockdown resulted in a
decrease in senescent cells viability in a similar fashion to ABT263, suggesting that ABT263
senolytic effect could be mediated by Bcl-XL (Figure 4.5C).
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Figure 4.5. Senolytic activity of ABT263 in senescent A549 cells is mediated by Bcl-XL. A. The expression of
anti-apoptotic BCL-2 family proteins in etoposide-induced senescent cells A549 cells were treated with etoposide
for 8 days to induce senescence, then ABT-263 was added for 48 hours B. The expression of BCL-XL and cleaved
caspase-3, indicative of apoptosis, was determined by Western blots after BCL-XL knockdown. C. A549 cells
were treated with etoposide for 6 days. Then, lentiviruses harboring shBCL-XL or shControl were infected
overnight. Two days later, numbers of viable cells were determined by trypan blue exclusion.
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4.3.3 ABT263 exerts senolytic activity against senescent H460 and LLC
cells

To examine the whether ABT263 is capable of exerting its senolytic activity in other lung cancer
cell lines, in a similar fashion to senescent A549 cells, H460 cells induced into senescence by
etoposide were exposed to ABT263 and were shown to be sensitive as well, as marked by reduced
cell viability (Figure 4.6A). In addition, the surviving population consisted of senescent, SA-βgal positive cells, suggesting that they might be amenable to a second bout of ABT263 (Figure
4.6B). We also examined the effect of ABT263 in a Lewis lung carcinoma cells (LLC, murine
lung cancer cell line) induced into senescence by etoposide (Figure 4.6C). Again, ABT263 was
able to reduce the viability of these cells (Figure 4.6D).

4.4 Discussion
The contribution of senescence to the pathogenesis of multiple age-associated pathologies is the
main driver for the development of drugs that can preferentially eliminate senescent cells. In the
seminal experiments, the elimination of a small portion of the accumulating senescent cells in an
aging mouse using a transgenic suicide gene model resulted in a remarkable improvement in
healthspan (241). Consequently, efforts have been focused on developing senolytic agents;
compounds that selectively clear senescent cells without compromising the viability of their
healthy neighbors (281). This approach is primarily based on promoting apoptosis in senescent
cells, which otherwise
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Figure 4.6. Effect of ABT263 on senescent H460 and LLC cells. A. Growth curves of H460 cells after induction
of senescence by etoposide (2 µM) followed by ABT263 (48 h exposure). Red arrow indicates when ABT263 was
added. B. SA-β-gal staining showing senescent H460 cells before and after ABT263 exposure. C. SA-β-gal
staining showing the induction of senescence in LLC by etoposide (1 μM for 24 h). D. Cell viability of LLC cells
induced to senescence by etoposide and then exposed to ABT263.
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appear to be capable of resisting cell death and maintaining survival for an extended period of time
(305). For example, senescent cells upregulate anti-apoptotic pathways, theoretically making them
susceptible to cell death by interfering RNA or small molecules that target these pathways (243).
Recently, a novel approach to selectively eliminate senescent cells in mice has paved the way for
a more efficient pharmacological clearance of such aging cells (287). This is based on the fact that
many senescent cells up-regulate the expression of Bcl2 family proteins, which serves to attenuate
or suppress apoptosis. Bcl2 inhibitors such as ABT737, ABT263 (oral version of ABT737) or
histone deacetylase inhibitors that act to reduce expression of Bcl2 proteins have been shown to
effectively target senescent cells (76,287). Additionally, several other compounds have been
proposed to possess a senolytic activity (Table 3).
Since senescent cells are major components of malignant tumors, and retain the potential to recover
after a period of dormancy, one could argue that combining these therapies with conventional prosenescence cancer therapy might actually improve treatment outcomes. In doing so, treatment with
senolytic agents could prevent (or significantly delay) proliferative recovery from therapy, and
disease recurrence. We have demonstrated that the exposure of senescent tumor cells to ABT263
results in effective killing of these cells and a potential delay in proliferative recovery. Both
preclinical studies and clinical trials are in progress combining ABT-263 and similar agents
simultaneously with chemotherapy and for extended periods after chemotherapy. A primary
element of the current work is that we are proposing to utilize ABT263 in sequence with
chemotherapy to eliminate tumor cells that have entered a state of senescence, with the goal of not
only enhancing the antitumor response but critically also preventing disease recurrence (Figure
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Targeted Pathway
Bcl2 anti-apoptotic family

Cell surface glycoproteins,
DPP4
HSP90
PI3K/Akt survival pathway
Tyrosine Kinase Receptors
Glucose and fatty acid
metabolism, AMPK,
autophagy
Histone deacetylase
inhibitors (HDACs)

Method of Elimination
ABT263 (Navitoclax)(287)
ABT-737 (76)
A1331852 (306)
A1155463 (306)
Elimination by antibodydependent cell-mediated
cytotoxicity (ADCC) (187)
17-DMAG (alvespimycin)
(293)
Quercetin (243)
Fisetin (306)
Dasatinib (243)
Phloretin (242)
Cytochalasin B (242)
Sodium oxamate (242)
Etomoxir (242)
Compound C (242)
Panobinostat (292)

Table 3. Senolytic agents. Summary of drugs that demonstrated the ability to clear senescent cells either in vitro
or in vivo, indicative of possible targets for the elimination of senescent cells
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4.1). Clinically, the ABT263 would be administered sequentially after exposure to the primary
chemotherapy for short durations at times of peak TIS, thereby reducing overall patient toxicity.
Furthermore, the patient could be treated with the primary form(s) of chemotherapy at lower, less
toxic doses that induce primarily senescence when followed by the senolytic agent.
We have also shown that ABT263 exerts its senolytic activity via its target Bcl-XL. Previously,
Bcl-XL (as well as Bcl-w) has been shown to mediate the senolytic activity of ABT737 in
eliminating senescent fibroblasts (76). It has been postulated that a Bcl-2 inhibitor that does not
interfere with Bcl-XL will not exert a senolytic action. Although not very well understood, Bcl-XL
appears to contribute to stabilizing the outer mitochondrial membrane in a different manner than
Bcl-2. This difference is clearer in tumor cells (MCF7 breast tumor cells) exposed to senescenceinducing therapy such as doxorubicin, where Bcl-XL plays the main role in promoting the survival
of these cells (307). Furthermore, we found that the selective Bcl-2 inhibitor ABT199 (venetoclax)
has no effect on senescent H460 cells (data not shown). This suggests that Bcl-XL plays a primary
role in the survival of senescent tumor cells especially in solid tumors. Accordingly, selective BclXL inhibitors, such as the experimental compounds A1331852 and A1155463, have successfully
eliminated several types of senescent cells including HUVEC, IMR90 and then to a lesser extent,
primary human preadipocytes (306). Similar to ABT263, these compounds did not have the same
effect on proliferating cells. Although ABT263 side effects can be controlled by careful dosing,
thrombocytopenia remains a dose-limiting adversity, resulting from the dual inhibition of Bcl-2
and Bcl-XL in bone marrow cells (308). Therefore, future use of these more selective Bcl-XL
inhibitors should provide a less toxic means to target senescent cells. Lastly, our data shows the
upregulation of Mcl-1 while being exposed to etoposide and undergoing senescence. Mcl-1 is
another member of the ABT263 family that plays a key role in regulating the mitochondrial
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pathway of apoptosis (309). Its upregulation during senescence suggests it might be an additional
target to induce killing in senescent tumor cells, especially after the development of S63845, a
small molecule that selectively targets Mcl-1 (310).
While the use of ABT263 and other senolytics sounds appealing, several obstacles should be
addressed. First, these drugs are associated with toxicities that might limit their combination with
pro-senescence therapy. Therefore, a main purpose of this work is to propose a model where these
drugs are used at lower doses that are less toxic, but can still effectively eliminate senescent tumor
cells. Moreover, the treatment regimen must be sequential, avoiding the added toxicity resulting
from conventional drug combination. The main purpose would be to use these drugs as clearance
therapy to eliminate residual senescent cells. Second, if the effect of ABT263 on senescent tumor
cells clinically will be equivalent to its effect in vitro, then the abrupt induction of cell death might
result in tumor lysis syndrome. Of course, this issue will depend on the mass of the targetable
senescent cells. Finally, a major concern is that ABT263 might eliminate beneficial non-tumor
senescent cells that contribute to several homeostatic functions in the body such as wound healing
(96). This concern should be weighed against the benefits of clearance therapy versus the medical
condition of each patient in an individualized manner. Furthermore, it is logical to establish an
approach whereby senolytic therapy can be administered following the confirmation of senescence
induction in patients receiving pro-senescence chemotherapy. The impact of ABT263 on existing,
or developing aging-related disorder in the presence of cancer has not been studied and
multimorbidity should be taken into consideration. All together, ABT263 provides a promising
means to eliminate senescent tumor cells; however, further characterization of this novel treatment
concept is required.
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4.5 Future studies
The successful demonstration of the ability of ABT263 to eliminate tumor cells invites for several
follow up questions. First, the ability of ABT263 to exert the same effect must be tested in vivo.
This requires the design of an experimental model where tumor xenografts are generated and
exposed to senescence-inducing therapy. We were able to establish a model where low-dose
etoposide can successfully induce senescence in A549 tumors implanted in NSG mice (Figure
4.7). Following the establishment of senescence in those tumors, the mice will receive low-dose
ABT263 by oral gavage in cycles. A cycle consists of daily doses of ABT263 for five days
followed by two, drug-free days to allow the animals to recover. In addition to measuring tumors
volume and mass, toxicity profiles should be also generated to assess if this sequential treatment
approach is advantageous in reducing the adverse effects that would be generated by simultaneous
combination of both drugs.
Second, it is essential to demonstrate the ability of ABT263 to eliminate tumor cells induced into
senescence by means other than DNA damaging agents in order to prove that the outcome is not a
result of conventional pharmacological additive effect. Models where tumor cells can be induced
into senescence using targeted therapy, such as palbociclib in breast tumor cells or androgendeprivation therapy in prostate tumor cells, both of which are unlikely to be associated with robust
DNA damage, should be used. The ability of ABT263 to eliminate senescent cells and interfere
with proliferative recovery from senescence must be tested in these other models to validate (i)
that its senolytic activity is consistent and (ii) that proliferative recovery is a consequence of
senescence. For a proof of principle we have demonstrated that when tumor cells fail to undergo
senescence due to the lack of p21Cip1 fail to recover from acute exposure to chemotherapy (Figure
4.8). In addition, these cells responded to DNA damage with primarily apoptosis instead of
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senescence in cases where p21Cip1 function was present. This means that even without using
ABT263, interfering with the senescent response to DNA damage decreases the survival potential
of senescent cells.
Lastly, it has been shown that simultaneous treatment of cisplatin and ABT-263 enhances
apoptosis in both p53 wild-type and mutant non-senescent NSCLC cells (311). However, it is not
known whether p53 is involved in apoptosis induced by ABT-263 in cells induced into senescence
by chemotherapy. To address this question, we started by knockout and knocking down p53 in
H460 and A549, respectively (Figure 4.9). Next, the effect of p53 deletion in chemotherapy
treatment and also subsequent treatment with senolytic agents for overall cell death (PI/Annexin
V on apoptosis and LDH release) must be determined. Reciprocally, doxycycline-inducible
expression of p53 in H1299 cells needs to be established where the effect of p53 overexpression
and ABT-263-induced apoptosis upon promotion of senescence cells can be determined. From
these studies the contribution of p53 to the apoptotic switch precipitated by ABT-263 in TIS cells
should be inferred to provide deeper mechanistic insight on the connection between senescence
and apoptosis.
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Figure 4.7. Detection of SA-β-gal activity in lung tumors after chemotherapy. Palpable A549 tumors in NSG
mice were treated with either vehicle or the indicated doses of etoposide in 5 injections over a week. After the last
dose the animals were euthanized, tumors collected and frozen sectioned. Sections were then stained for SA-β-gal
both histochemically (X-Gal - upper panel) and using fluorescent microscopy (C12-FDG - lower panel). Increase
in blue (upper) or fluorescent green (lower) SA-β-gal staining with etoposide exposure.
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Figure 4.8. Cells that fail to senesce in response to chemotherapy
do not recover. A. Histochemical SA-β-gal
staining, C12FDG staining, and TUNEL assay comparing the response of HCT116 WT and p21Cip1 (-/-) cells to
etoposide (1 µM) exposure for 24 h. All assays were performed 48 hours following drug removal B. Temporal
growth assessment of both HCT116 WT and p21Cip1 (-/-) after etoposide (1 µM) exposure for 24 h.
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Figure 4.9. Knockout of p53 in A549 cells using shRNA and H460 cells using CRISPR/Cas9.
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Chapter Five: Etoposide-induced senescence and
proliferative recovery occur independently of autophagy
in H460 lung cancer cells

5.1 Introduction
Autophagy is a homeostatic process that involves lysosomal-dependent intracellular degradation
of organelles and damaged proteins (312). At basal levels, autophagy contributes to several
physiological processes and can be further induced in response to a variety of cellular stresses
including nutritional deprivation, oxidative stress, accumulation of misfolded proteins and
endoplasmic reticulum (ER) stress and DNA damage (313–315). Once the autophagic response is
triggered, double-layered membranous vesicles, called autophagosomes, start sequestering
cytoplasmic structures directed for degradation. Several autophagy-related (ATG) genes have been
described which play diverse roles in cargo recognition, sequestration and delivery to the
lysosomes (316). Autophagy is further regulated by a network of signaling pathways that involve
PI3K/mTOR, AMPK, and the Ras/PKA pathway amongst others (317). Autophagy has been
extensively studied as a component of several pathologies including cancer (316), and similar to
senescence, has been established as a primary response to cancer therapy in tumor cells (318).
Several observations have closely linked senescence and autophagy together. First, as in the case
of senescence, autophagy plays a powerful tumor suppressive function as many ATG genes are
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frequently mutated or deleted in transforming cells, resulting in the accumulation of free radicals
and further genomic instability (319). Furthermore, autophagy contributes to forms of tumor
dormancy where it facilitates the survival of tumor cells (320). More importantly, therapy-induced
senescence in tumor cells is almost always accompanied by a robust autophagic vacuolation
(62,220). However, the connection between autophagy and senescence remains enigmatic (321)
in that while autophagy is believed to facilitate the transition into senescence (322–325), other
evidence suggests that autophagy inhibition can either promote or prevent senescence (326,327).
Both senescence and autophagy contribute to tumor cell survival and cell fate, but the putative
nature of their interaction has not been fully resolved.
As we have established that therapy-induced senescence in tumor cells is not necessarily a terminal
process, in this chapter we continue using etoposide to induce senescence in lung cancer cells in
efforts to investigate whether autophagy blockade interferes with the ability of the cells to maintain
their senescent state and to recover proliferative capacity. Utilization of pharmacological and
genetic approaches to inhibit autophagy determined that autophagy was functionally noncytoprotective is disagreement with its historical role as a survival mechanism. Furthermore,
autophagy inhibition did not affect sensitivity of the tumor cells to etoposide, their capacity to
undergo and maintain senescence or to recover proliferative capacity.

5.2 Experimental procedures
5.2.1 Cell lines
The wild-type (WT) TP53 H460 cell lung cancer cell line was generously provided by Dr. Richard
Moran and Dr. Charles Chalfant, respectively, at Virginia Commonwealth University. The ATG5knocked down H460 variant was generated as follows. Mission shRNA bacterial stocks for ATG5
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were purchased from Sigma-Aldrich (TRCN00151963) and lentivirus generation was conducted
in the HEK 293TN cells. Cotransfection was performed using lipofectamine (Invitrogen, 11668–
019) with a packaging mixture of psPAX2 and pMD2.G constructs (Addgene, 12260, 12259).
After 48 h, viruses shed into the media were collected and used to infect H460 cells under
ultrasonic centrifugation for 2 h. Selection was performed in Puromycin (Sigma-Aldrich, P8833)
(1-2 μg/ml). All cells were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum
(Thermo Scientific, SH30066.03), 100 U/ml penicillin G sodium (Invitrogen, 15140–122), and
100 μg/ml streptomycin sulfate (Invitrogen, 15140–122). Cells were maintained at 37°C under a
humidified, 5% CO2 atmosphere at subconfluent densities. At all etoposide concentration (SigmaAldrich, E1383) utilized, cells were exposed to the drug-containing medium for 24 h, followed by
replacement with fresh medium. Incubation with Chloroquine (CQ, 10 µM) or Bafilomycin A1
(Baf, 5 nM) was utilized to interfere with lysosomal acidification and autophagosome/lysosome
fusion, respectively. Cells were treated with the autophagy inhibitors for 3 h prior to the subsequent
exposure to both etoposide and the autophagy inhibitor for an additional 24 h to ensure blockade
of autophagy. Drugs were protected from light during handling.

5.2.2 Cell Viability and Clonogenic Survival
Growth curves were generated based on cell viability as assessed by Trypan blue exclusion. Cells
were seeded, treated (on day 0), and counted at the indicated time points following the removal of
the drug from the medium. For clonogenic assays, cells were seeded, pre-treated with CQ (10 µM)
or Baf (5 nM) for 3 h, then treated with etoposide (0.25, 0.5, 1.0, or 5 µM) alone or in combination
with CQ or Baf; drugs were removed and replaced with fresh media after 24 h. Cells were
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incubated for 7 days, then fixed with methanol, stained with crystal violet, and counted (ColCount,
Discovery Technology International).

5.2.3 Analysis of senescence and autophagy by flow cytometry and
microscopy
All of the flow cytometry analyses were performed using BD FACSCanto II and BD FACSDiva
software at the Virginia Commonwealth University Flow Cytometry Core Facility. For C 12FDG
(Life Technologies, D2893) and acridine orange analyses, 10,000 cells per replicate within the
gated region were analyzed. Three replicates for each condition were analyzed in each independent
experiment. Labeling procedures, gating, and analysis followed our previously published protocols
with minor adjustment for the tested cell line (62,220,253). For β-galactosidase and C12FDG
staining β-galactosidase labeling was performed as previously described by Dimri et al(80) and in
our previous publications(62,220,253). Phase contrast images were taken using an Olympus
inverted microscope (20X objective, Q-Color3™ Olympus Camera; Olympus, Tokyo, Japan). The
C12FDG staining protocol was adopted from Debacq-Chainiaux et al (185).

5.2.4 Western blotting and immunofluorescence
Western blotting was performed as previously described (62,220,253). Primary antibodies were
used at a 1: 1000 dilution except for GAPDH (1:8000 dilution). For immunofluorescence cells
were fixed with methanol, permeabilized with 0.1% Triton X-100, and blocked with 1% bovine
serum albumin (BSA). Cells were exposed to a 1:100 dilution of the p21 antibody and incubated
overnight at 4°C, followed by exposure to the secondary antibody for 1 h at room temperature.
After incubation, cells were mounted with DAPI and imaging was performed with an Olympus
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inverted microscope (20X objective, Q-Color3™ Olympus Camera, 555 filter and UV light,
Olympus, Tokyo, Japan). Primary antibodies: SQSTM1/p62 (BD Biosciences, 610497), ATG5
(Cell Signaling Technology, 2630), LC3B (Cell Signaling Technology, 3868), p21Cip1 (BD,
610234).

5.2.5 TUNEL assay
Quantification of apoptotic cells via flow cytometry was achieved per the manufacturer’s
instructions (AnnexinV-FITC apoptosis detection kit, BD Biosciences, 556547). For the terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, cells were harvested and
centrifuged at 10,000 rpm for 5 min onto slides (Shandon Cytospin 4, Thermal Electron Corp) 48
h after etoposide removal. Slides were fixed with 4% formaldehyde for 10 min and then washed
with PBS for 5 min at room temperature. The cells were then fixed with a 1:2 dilution of acetic
acid and ethanol for 5 min, followed by staining with a 1:1,000 dilution of DAPI at room
temperature. Coverslips were sealed using clear nail polish and apoptosis was assessed by
evaluating three fields per condition with an Olympus inverted microscope (20X objective, QColor3™ Olympus Camera, 488 filter and UV light, Olympus, Tokyo, Japan).

5.3 Results
5.3.1 Senescence and autophagy are collaterally induced in H460 NSCLC
cells in response to etoposide
As we have demonstrated before, as early as 3 days after the initiation of exposure to etoposide,
H460 cells exhibit numerous features collectively indicative of senescence, specifically a flattened
and enlarged appearance with abundant granulation, and histochemical staining for SA-β-gal
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activity. As would have been anticipated based on the fact that etoposide was previously shown
to promote autophagy in A549 and U1810 NSCLC cell lines (328), autophagy was also evident in
the H460 cells exposed to etoposide, as indicated by increased formation of acridine orangestained acidic vesicular organelles in the H460 cells (Figures 5.1A and B).
LC3B is soluble protein that targets damaged cellular components for sequestration in the
autophagosome. During autophagosomal maturation, LC3B becomes lipidated by conjugating to
phosphatidylethanolamine (conversion of LC3 from form I to form II) (329). LC3BII is also
subject to lysosomal degradation when autophagy goes to completion; however, measuring the
localization and lipidation of LC3B is used as a marker for autophagy induction and formation of
autophagosomes. On the other hand, p62/SQSTM1 is an adapter protein that binds to LC3B and
serves as a receptor for ubiquitinated proteins targeted for degradation (330). p62/SQSTM1
degradation is frequently measured as a sign of autophagy completion. Accordingly, the induction
of autophagy in H460 cells exposed to etoposide was confirmed based on the increased formation
of GFP-LC3 puncta indicative of autophagosomes formation (Figure 5.1C). Furthermore,
etoposide exposure resulted in increased lipidation of LC3 and degradation of p62/SQTSM1
(Figure 5.1D), indicating that the autophagic process is progressing to completion (i.e. autophagic
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Figure 5.1. Autophagy as a primary response to etoposide in H460 NSCLC cells. A. Fluorescence microscopy
showing concentration-dependent increase in acridine orange-stained vacuoles induced by 0.25, 0.5, and 1 µM
etoposide B. Quantification of acidic vesicular organelles (AVOs) by FACS analysis in response to increasing
concentrations of etoposide. C. Fluorescence microscopy showing increased GFP-LC3 puncta in response to
etoposide (1µM) exposure. Imaging performed 48 h after drug removal. (20x objective). The number of LC3B
puncta formed per cell is provided in the bar graph.
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flux). Collectively, these data indicate that etoposide induces a senescent growth arrest in H460
cells accompanied by robust autophagy.

5.3.2 Autophagy plays a non-cytoprotective role in response to etoposide
in H460 cells
Autophagy has historically been considered a survival response under conditions of
nutrient deprivation or hypoxia, as well as a mechanism of resistance to therapy (331–335). To
determine whether autophagy might be interfering with the antiproliferative and/or potential
cytotoxic effects of etoposide in the H460 cells, autophagy was suppressed using both
pharmacological and genetic strategies, and the impact on sensitivity to etoposide was monitored.
Cells were pretreated for 3 hours with the autophagy inhibitors chloroquine (CQ, 10 µM) or
bafilomycin A1 (Baf, 5 nM) followed by 24 hours of exposure to etoposide in the presence of the
CQ or Baf. The presence of CQ and Baf resulted in failure of lysosomal acidification, which is
reflected by the yellow staining of vacuoles by acridine orange (Figure 5.2A); autophagy
inhibition was confirmed by decreased degradation of p62/SQTSM1 in the presence of CQ or Baf
(Figure 5.2B). Inhibition of autophagy did not alter sensitivity to etoposide as determined by
clonogenic survival assays (Figure 5.2C) (except moderately with Baf at 1 µM etoposide).
Autophagy was also blocked genetically using shRNA-meditated knockdown of Atg5.
Confirmation of gene silencing is shown by immunoblotting where p62/SQTSM1 levels are
increased and LC3BI to LC3BII conversion is reduced (Figure 5.3A). Furthermore, Atg5
knockdown was maintained throughout a time course of 7 days marked by failure of p62/SQTSM1
degradation (Figure 5.3B) Silencing of Atg5 did not sensitize the H460 NSCLC cells to etoposide
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Figure 5.2. Pharmacological inhibition of autophagy does not affect the survival of etoposide-induced
senescent H460 cells. A. Fluorescence microscopy showing failure of lysosomal acidification following CQ (10
µM) or Baf (5 nM) co-treatment with etoposide (1 µM). Cells were pretreated with CQ and Baf followed by an
additional 24 h with etoposide. Images were taken 48 h after drug removal. Nuclei stained with Hoechst 33342
(20x objective). B. Western blot showing autophagy blockade by CQ (10 µM) and Baf (5 nM) based on levels of
p62/SQSTM1 C. Clonogenic survival assay showing influence of CQ (10 µM) or Baf (5 nM) on sensitivity of
H460 cells to etoposide. Cells were pretreated with CQ or Baf for 3 h followed by co-treatment with etoposide for
24 h. Colonies were counted 7 days following removal of drugs and replacement with fresh medium. Bars represent
mean survival ± SD relative to untreated controls (α=0.05/3, * p<0.016).
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Figure 5.3. Genetic inhibition of autophagy does not affect the survival of etoposide-induced senescent H460
cells. A. Western blot following shRNA-mediated knockdown of Atg5. B. Western blot showing p62/SQSTM1
degradation over time in autophagy-proficient cells after etoposide (1 μM) treatment and p62/SQSTM1
accumulation in Atg5-silenced autophagy-deficient cells after etoposide (1 μM) treatment indicating that genetic
silencing of Atg5 using shRNA results in autophagy inhibition sustained for at least 7 days after drug removal. C.
Clonogenic survival assay comparing sensitivity of shControl and shAtg5 H460 cells in response to multiple
etoposide concentrations. Bars represent mean survival ± SD relative to untreated controls (α=0.05/3, * p<0.016).
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(except for a small effect at the 0.25 µM concentration)(Figure 5.3C). These studies indicate that
autophagy inhibition does not alter the drug sensitivity of H460 tumor cells as they undergo
senescence in response to etoposide, indicating that etoposide-induced autophagy is noncytoprotective (336,337).

5.3.3 Autophagy inhibition does not interfere with the ability of H460
cells to senescence or to recover proliferative capacity after senescence
induction
In previous studies of radiation-induced autophagy and senescence in HCT-116 colon carcinoma
cells, we demonstrated a direct correspondence between the extent of autophagy and senescence,
where both responses were related to the extent of DNA damage (220). However, in this work, as
well as studies of doxorubicin-induced autophagy and senescence in breast tumor cells (62), we
reported that the two responses are clearly dissociable. Our studies further demonstrate that the
senescence induced by etoposide in the H460 cells is not affected by autophagy, as genetic
silencing of autophagy failed to influence the promotion of senescence by etoposide (Figure 5.4A
and B).
H460 human NSCLC cells undergo growth arrest followed by proliferative recovery upon
exposure to etoposide, a mainstay chemotherapeutic agent. To examine whether recovery might
be dependent on maintenance of autophagy, recovery was evaluated in the presence of the
pharmacological autophagy inhibitors as well as with ATG5 silencing.

133

A

B

% C 12FDG Positive Cells

100

H460
shC
shAtg5

80
60
40
20
0

Control

C
5x105
4x105

# of Viable Cells

Eto

Day3

3x105

D

H460
Control
CQ (10 uM)
Eto (1 uM)
Eto+CQ

2x105
105
0

Senescent growth arrest

0

2

E
7x10 5

# of Viable Cells

6x10 5
5x10 5
4x10 5

4

Proliferative
recovery

6

8

Days
H460
shC Control
shAtg5 Control
shC Eto (1 uM)
shAtg5 Eto (1 uM)

3x10 5
2x10 5
105
0

Senescent growth arrest

0

2

4

Proliferative
recovery

6

8

Days
Figure 5.4. Autophagy inhibition
does not interfere with the ability of cells to senesce or to recover
proliferative capacity after senescence induction. A. Percent senescence based on C12FDG staining at day 3
post-etoposide exposure in shControl cells and shAtg5 cells. B. Etoposide-induced senescence in both autophagyproficient and autophagy-deficient H460 cells by staining for SA-β-gal activity (20x objective). C. and D.
Temporal responses to etoposide in H460 cells after pharmacological autophagy inhibition. Viable H460 cell
number was determined at the indicated days following etoposide exposure in combination with 10 µM CQ (left
panel) or 5 nM Baf (right panel). E. Temporal response to etoposide in shControl H460 cells and H460 cells with
knockdown of Atg5.
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The temporal response studies in Figures 5.4C and D indicate that neither CQ nor Baf was able
to alter the profile of growth arrest; furthermore, proliferative recovery occurred in the cells treated
with etoposide both in the absence and presence of CQ or Baf . Furthermore, growth arrest and
proliferative recovery profiles were virtually identical in H460 cells where Atg5 was silenced as
in the autophagy-competent cells (Figure 5.4E).

5.4. Discussion
Both senescence and autophagy are established responses to stress resulting from DNA damage
and oxidative injury (47,159,312).When apoptosis is not the predominant response to therapy,
senescence represents a major determinant of cell fate, where cells remain in a growth-abrogated
state while maintaining their metabolic activity (181,203). Senescence could represent one basis
for tumor cells remaining dormant for prolonged periods of time (140). It has been suggested that
the regulatory pathways of both processes are intertwined (338–340) and it is clear that senescent
cells develop abundant acidic vacuoles (341). However, the relationship of the autophagic
response to the induction and maintenance of senescence does not appear to be consistent across
the types of stimuli that promote these responses or the cell lines in which they have been studied
(327).
While autophagy might have been anticipated to contribute to maintenance of the metabolic
integrity of the senescent tumor cells, inhibition of autophagy did not appear to affect the survival
of senescent cells. Furthermore, inhibition of autophagy failed to prevent the recovering population
from resuming growth. Consequently, while autophagy may represent an intrinsic component of
the senescent response elicited by cancer therapy, the current studies indicate that autophagy plays
a minor, if any, role in facilitating proliferative recovery in this system or interfering with the fate
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of the senescent cells. This may be related to the fact that the etoposide-induced autophagy is
nonprotective in function, as discussed below.
Although the bulk of the literature has focused on the cytoprotective function(s) of autophagy
(342,343) we and others have shown in a number of studies that interference with autophagy failed
to alter drug or radiation sensitivity or to promote apoptosis (220,336,337). While the noncytoprotective function of radiation-induced autophagy was previously shown to be dependent on
the cells being mutant or null in p53 (337), it is clear in the current work that autophagy induced
by etoposide in the p53 wild-type H460 cells is non-cytoprotective. These findings are consistent
with a recent report by Eng et al (344) demonstrating non-cytoprotective autophagy induced by
more than 30 chemotherapeutic drugs in the A549 NSCLC cell line. Furthermore, previous studies
addressing the involvement of autophagy in promoting an effective antitumor immune response
following chemotherapy also identified the nonprotective form of autophagy (although this
terminology had not been established at that time) (345). Taken together, these data suggest that
the function of autophagy should be further investigated in other cancer models, with particular
attention to its relationship with cellular senescence (58,89,93,209).
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